Philip Scheltens
#45,429
Most Influential Person Now
Alzheimer researcher
Philip Scheltens's AcademicInfluence.com Rankings
Philip Scheltensbiology Degrees
Biology
#1813
World Rank
#2944
Historical Rank
Neuroscience
#152
World Rank
#160
Historical Rank
Philip Scheltensphilosophy Degrees
Philosophy
#1924
World Rank
#3386
Historical Rank
Logic
#361
World Rank
#704
Historical Rank
Download Badge
Biology Philosophy
Why Is Philip Scheltens Influential?
(Suggest an Edit or Addition)According to Wikipedia, Philip Scheltens is a Dutch professor of neurology and founder of the Alzheimer Centre, Amsterdam University Medical Centers, location VUmc in Amsterdam. Early life, education and career Philip Scheltens was born in Dordrecht, Netherlands, where he grew up in a family of four. His father led a factory. His grandfather developed Alzheimer’s disease in those years, which made an impression on his grandson. Philip attended the Christelijk Lyceum, where he graduated in 1976. As a teenager he was an enthusiastic drummer in several bands and was fascinated by science and mechanics.
Philip Scheltens's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) (12716)
- NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018) (4523)
- Consistent resting-state networks across healthy subjects (2006) (4042)
- Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria (2007) (4004)
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (2014) (2513)
- Risk of dementia in diabetes mellitus: a systematic review (2006) (1852)
- Revising the definition of Alzheimer's disease: a new lexicon (2010) (1793)
- A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease (2014) (1634)
- A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT (2001) (1575)
- The clinical use of structural MRI in Alzheimer disease (2010) (1556)
- Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. (1992) (1449)
- Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. (1997) (1280)
- Small-world networks and functional connectivity in Alzheimer's disease. (2006) (1187)
- Defeating Alzheimer's disease and other dementias: a priority for European science and society (2016) (1172)
- Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria (2016) (1163)
- CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. (2009) (1139)
- Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
- Reduced resting-state brain activity in the "default network" in normal aging. (2008) (1099)
- Alzheimer's disease (2016) (1006)
- A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers (2016) (1004)
- A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging (1993) (896)
- Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. (2009) (845)
- Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study (2005) (743)
- White matter hyperintensities, cognitive impairment and dementia: an update (2015) (726)
- Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis (1998) (645)
- Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline (2007) (639)
- Research criteria for subcortical vascular dementia in clinical trials. (2000) (631)
- Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations (2010) (596)
- Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer’s Disease (2006) (568)
- Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study (2009) (566)
- Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease (2004) (556)
- Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' (1998) (548)
- Loss of ‘Small-World’ Networks in Alzheimer's Disease: Graph Analysis of fMRI Resting-State Functional Connectivity (2010) (540)
- Cognitive impairment in heart failure: A systematic review of the literature (2007) (505)
- EFNS guidelines for the diagnosis and management of Alzheimer’s disease (2010) (486)
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup (2011) (485)
- Advances in the early detection of Alzheimer's disease (2004) (484)
- Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. (2015) (476)
- Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. (2003) (471)
- Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) (471)
- A comprehensive study of gray matter loss in patients with Alzheimer’s disease using optimized voxel-based morphometry (2003) (432)
- Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates (2012) (427)
- The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials (2016) (418)
- Epidemiology and risk factors of dementia (2005) (416)
- Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers (2017) (414)
- Impact of Age-Related Cerebral White Matter Changes on the Transition to Disability – The LADIS Study: Rationale, Design and Methodology (2004) (412)
- White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia, and normal aging (1999) (412)
- Association of gait and balance disorders with age-related white matter changes (2008) (402)
- Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. (1998) (392)
- Cortico‐hippocampal communication by way of parallel parahippocampal‐subicular pathways (2000) (391)
- Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance (2012) (388)
- Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort (2009) (384)
- Circadian rest—activity rhythm disturbances in alzheimer's disease (1996) (384)
- Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. (1996) (376)
- Early-versus late-onset Alzheimer's disease: more than age alone. (2010) (372)
- The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. (2015) (370)
- Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions (2003) (368)
- Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period: The Leukoaraiosis and Disability Study (2008) (360)
- Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion (2002) (358)
- Alzheimer's disease: connecting findings from graph theoretical studies of brain networks (2013) (352)
- Consensus classification of posterior cortical atrophy (2017) (350)
- Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging (1995) (349)
- Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability (1995) (349)
- Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory (2009) (347)
- Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment (2004) (347)
- Brain Imaging in Patients With Diabetes (2006) (346)
- Hippocampal atrophy rates in Alzheimer disease (2009) (342)
- Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment (2002) (337)
- Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment (2012) (333)
- Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. (2010) (330)
- Activity Dependent Degeneration Explains Hub Vulnerability in Alzheimer's Disease (2012) (328)
- Current state of Alzheimer’s fluid biomarkers (2018) (327)
- Optimizing patient care and research: the Amsterdam Dementia Cohort. (2014) (325)
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease (2017) (322)
- Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment (1999) (320)
- Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study (2007) (304)
- Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease (2006) (304)
- Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges (2015) (304)
- Impact of White Matter Hyperintensities Scoring Method on Correlations With Clinical Data: The LADIS Study (2006) (302)
- Visual assessment of posterior atrophy development of a MRI rating scale (2011) (296)
- Drug development in Alzheimer’s disease: the path to 2025 (2016) (295)
- Visual Rating of Age-Related White Matter Changes on Magnetic Resonance Imaging: Scale Comparison, Interrater Agreement, and Correlations With Quantitative Measurements (2003) (291)
- White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. (1992) (286)
- Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. (2015) (285)
- White Matter Changes on CT and MRI: An Overview of Visual Rating Scales (1998) (283)
- Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. (1998) (282)
- Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial (2010) (281)
- Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge (2015) (277)
- The clinical profile of right temporal lobe atrophy. (2004) (274)
- EEG synchronization in mild cognitive impairment and Alzheimer's disease (2003) (272)
- Precuneus atrophy in early-onset Alzheimer’s disease: a morphometric structural MRI study (2007) (271)
- Midlife Blood Pressure and the Risk of Hippocampal Atrophy: The Honolulu Asia Aging Study (2004) (270)
- Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. (2006) (269)
- On the path to 2025: understanding the Alzheimer’s disease continuum (2017) (269)
- EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia (2012) (267)
- Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease (2009) (267)
- Frontotemporal dementia and its subtypes: a genome-wide association study (2014) (262)
- Heterogeneity in age-related white matter changes (2011) (262)
- Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort (2012) (262)
- Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele (2011) (261)
- Small Vessel Disease and General Cognitive Function in Nondisabled Elderly: The LADIS Study (2005) (259)
- The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? (2014) (258)
- Generalized Synchronization of MEG Recordings in Alzheimer’s Disease: Evidence for Involvement of the Gamma Band (2002) (257)
- Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease (2015) (256)
- Vascular cognitive impairment (2018) (254)
- Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. (2012) (252)
- White matter tract integrity in aging and Alzheimer's disease (2009) (252)
- CT and MRI Rating of White Matter Lesions (2002) (246)
- 2001–2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease? (2011) (246)
- New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) (246)
- EEG synchronization likelihood in mild cognitive impairment and Alzheimer's disease during a working memory task (2004) (240)
- Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study (2000) (240)
- Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. (2008) (238)
- Blood-brain barrier p-glycoprotein function in Alzheimer's disease (2011) (238)
- A systematic review of Instrumental Activities of Daily Living scales in dementia: room for improvement (2008) (232)
- Functional MR imaging in Alzheimer's disease during memory encoding. (2000) (229)
- Disturbed fluctuations of resting state EEG synchronization in Alzheimer's disease (2005) (227)
- fMRI of visual encoding: Reproducibility of activation (1999) (224)
- Noradrenaline mediates amygdala activation in men and women during encoding of emotional material (2005) (220)
- Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. (2015) (215)
- Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. (2013) (214)
- Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study (2001) (214)
- Mild cognitive impairment (2005) (213)
- Patterns of Cerebral Atrophy in Dementia with Lewy Bodies Using Voxel-Based Morphometry (2002) (207)
- Behavioral symptoms in mild cognitive impairment (2004) (205)
- Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) (204)
- Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) (204)
- Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes (2018) (203)
- Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. (2015) (201)
- Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. (2007) (200)
- Medial temporal lobe atrophy on MRI in dementia with Lewy bodies (1999) (200)
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials (2016) (200)
- Patients With Alzheimer Disease With Multiple Microbleeds: Relation With Cerebrospinal Fluid Biomarkers and Cognition (2009) (199)
- Brain Aging in Very Old Men With Type 2 Diabetes (2006) (199)
- Consensus guidelines for lumbar puncture in patients with neurological diseases (2017) (197)
- Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease (2012) (196)
- CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment (2007) (193)
- Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease (2011) (191)
- Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia (2001) (190)
- Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia (2018) (188)
- Measuring progression of cerebral white matter lesions on MRI (2004) (188)
- Familial aggregation in frontotemporal dementia (1998) (187)
- The significance of medial temporal lobe atrophy (2007) (186)
- Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies (2014) (185)
- Profile of Cognitive Impairment in Chronic Heart Failure (2007) (184)
- Age, Hypertension, and Lacunar Stroke Are the Major Determinants of the Severity of Age-Related White Matter Changes (2006) (183)
- Amsterdam Dementia Cohort: Performing Research to Optimize Care (2018) (183)
- World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia (2019) (183)
- Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS Study (2009) (182)
- The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity (2015) (182)
- Pathophysiologic Mechanisms in the Development of Age-Related White Matter Changes of the Brain (1998) (180)
- A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease (2009) (179)
- Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer’s disease (2005) (179)
- Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints (2013) (178)
- Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease (2013) (176)
- Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease (2015) (175)
- Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. (1997) (175)
- Imaging markers for Alzheimer disease (2013) (174)
- Diabetic encephalopathy: a concept in need of a definition (2006) (174)
- Endogenous cortisol level interacts with noradrenergic activation in the human amygdala (2007) (171)
- Within-subject reproducibility of visual activation patterns with functional magnetic resonance imaging using multislice echo planar imaging. (1998) (170)
- Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study (2016) (170)
- MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases (2016) (170)
- Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus. (2007) (170)
- Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding (2009) (168)
- Impact of molecular imaging on the diagnostic process in a memory clinic (2013) (166)
- Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy (2006) (166)
- Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. (1992) (165)
- Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. (2005) (164)
- Age and diagnostic performance of Alzheimer disease CSF biomarkers (2012) (163)
- Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias (2020) (163)
- The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia (2004) (160)
- Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease (2008) (160)
- Incidence of depression and anxiety in the spouses of patients with dementia: a naturalistic cohort study of recorded morbidity with a 6-year follow-up. (2010) (160)
- Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study (2007) (159)
- Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease (2013) (159)
- Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease (2004) (159)
- Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease (2000) (159)
- Tau and p-tau as CSF biomarkers in dementia: a meta-analysis (2011) (157)
- Magnetoencephalographic analysis of cortical activity in Alzheimer's disease: a pilot study (2000) (154)
- Regional Distribution of White Matter Hyperintensities in Vascular Dementia, Alzheimer’s Disease and Healthy Aging (2004) (154)
- Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease (2002) (152)
- Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia: An Interobserver Study (2003) (151)
- Model‐free group analysis shows altered BOLD FMRI networks in dementia (2009) (151)
- Quantitative MRI changes in gadolinium‐DTPA enhancement after high‐dose intravenous methylprednisolone in multiple sclerosis (1991) (150)
- Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer’s disease (2003) (149)
- 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial (2017) (148)
- Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI (2007) (145)
- Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. (2014) (143)
- Microglial activation in healthy aging (2012) (143)
- Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET (2012) (142)
- Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study (2013) (142)
- Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations (2013) (141)
- Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. (2008) (141)
- Injury markers predict time to dementia in subjects with MCI and amyloid pathology (2012) (141)
- Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis (2005) (140)
- CSF biomarker levels in early and late onset Alzheimer's disease (2009) (140)
- Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease (2005) (139)
- Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage (2013) (139)
- Glucocorticoids Decrease Hippocampal and Prefrontal Activation during Declarative Memory Retrieval in Young Men (2007) (139)
- Incident lacunes influence cognitive decline (2011) (139)
- White matter lesion progression (2004) (138)
- Biomarkers for Alzheimer's disease therapeutic trials (2011) (138)
- Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force (2013) (137)
- Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI study. (2005) (136)
- Brain magnetic resonance imaging abnormalities in patients with heart failure (2007) (136)
- Test-retest analysis with functional MR of the activated area in the human visual cortex. (1997) (135)
- Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PET (2009) (134)
- Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. (2009) (133)
- The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease (2020) (133)
- Inflammatory markers in AD and MCI patients with different biomarker profiles (2009) (133)
- Progression of Mild Cognitive Impairment to Dementia: Contribution of Cerebrovascular Disease Compared With Medial Temporal Lobe Atrophy (2009) (131)
- Hippocampal atrophy in Alzheimer disease: Age matters (2006) (130)
- Brain Lesions on MRI in Elderly Patients with Type 2 Diabetes Mellitus (2006) (129)
- Visualizing brain activation during planning: the tower of London test adapted for functional MR imaging. (2000) (128)
- Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study (2006) (128)
- Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume (2007) (127)
- Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients (1994) (127)
- Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging (2011) (127)
- Longitudinal changes of CSF biomarkers in memory clinic patients (2007) (127)
- CSF biomarkers predict rate of cognitive decline in Alzheimer disease (2009) (126)
- Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia (2005) (125)
- P2-313 Prevalence and severity of microbleeds in a memory clinic setting (2006) (125)
- White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. (1998) (123)
- Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study (2009) (123)
- Preclinical AD predicts decline in memory and executive functions in subjective complaints (2013) (123)
- Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. (2012) (123)
- Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study (1997) (121)
- Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI (2013) (121)
- Assessing mental flexibility: neuroanatomical and neuropsychological correlates of the trail making test in elderly people (2010) (121)
- The “rights” of precision drug development for Alzheimer’s disease (2019) (120)
- Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. (2013) (119)
- White matter lesions and hippocampal atrophy in Alzheimer’s disease (2004) (118)
- Neuropsychological correlates of a right unilateral lacunar thalamic infarction (1999) (118)
- Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study (2015) (118)
- Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. (2014) (117)
- MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. (1997) (117)
- Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
- The two-year incidence of depression and anxiety disorders in spousal caregivers of persons with dementia: who is at the greatest risk? (2015) (115)
- Physical Activity Prevents Progression for Cognitive Impairment and Vascular Dementia: Results From the LADIS (Leukoaraiosis and Disability) Study (2012) (115)
- P-Glycoprotein Function at the Blood–Brain Barrier: Effects of Age and Gender (2012) (115)
- CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease (2008) (114)
- Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease (2009) (113)
- Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies (2018) (113)
- Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. (2012) (112)
- Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. (2018) (112)
- Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study. (2006) (112)
- MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population (2009) (111)
- Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. (2008) (111)
- Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same? (2005) (111)
- EFNS task force: the use of neuroimaging in the diagnosis of dementia (2012) (111)
- The functional basis of ocular dominance: functional MRI (fMRI) findings (1996) (110)
- The probabilistic model of Alzheimer disease: the amyloid hypothesis revised (2021) (110)
- Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients (2003) (110)
- Limitations of Clincal Criteria for the Diagnosis of Vascular Dementia in Clinical Trials: Is a Focus on Subcortical Vascular Dementia a Solution? (2000) (110)
- The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer’s Disease: A Randomised Controlled Study (2014) (110)
- Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study (2005) (109)
- Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease? (2005) (109)
- Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas (2018) (109)
- Multicenter assessment of reliability of cranial MRI (2006) (108)
- Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia (2008) (108)
- Can nutrients prevent or delay onset of Alzheimer's disease? (2010) (107)
- Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia (2018) (107)
- CSF biomarkers in relationship to cognitive profiles in Alzheimer disease (2009) (107)
- Global dynamical analysis of the EEG in Alzheimer’s disease: Frequency-specific changes of functional interactions (2008) (106)
- Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. (2015) (106)
- Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC (2003) (106)
- Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort (2015) (105)
- Selective impairment of hippocampus and posterior hub areas in Alzheimer’s disease: an MEG-based multiplex network study (2017) (104)
- Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study (2010) (104)
- Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study (2004) (104)
- Inflammatory biomarkers in Alzheimer's disease plasma (2019) (104)
- An algorithmic approach to structural imaging in dementia (2013) (103)
- Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study (2010) (102)
- Hippocampal shape analysis in Alzheimer’s disease: A population-based study (2007) (102)
- Relationship between periventricular and deep white matter lesions and depressive symptoms in older people. The LADIS Study (2006) (102)
- The diagnostic value of electroencephalography in mild senile Alzheimer's disease (1999) (100)
- Whole-brain atrophy rate in Alzheimer disease (2008) (100)
- Single-Subject Grey Matter Graphs in Alzheimer's Disease (2013) (100)
- Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study (2007) (99)
- The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia (2007) (99)
- Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure (1998) (99)
- Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study (2006) (98)
- Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia (2013) (98)
- EFNS‐ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease (2015) (98)
- Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID‐19 pandemic, now and in the future (2020) (97)
- Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies (2016) (97)
- Simplified parametric methods for [11C]PIB studies (2008) (96)
- Phase-Contrast Cine Mr Imaging of Normal Aqueductal CSF Flow (1994) (96)
- Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease (2015) (96)
- Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. (2004) (95)
- MRI-Defined Subcortical Ischemic Vascular Disease: Baseline Clinical and Neuropsychological Findings (2009) (94)
- White Matter Lesion Progression in LADIS: Frequency, Clinical Effects, and Sample Size Calculations (2012) (94)
- Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project (2018) (93)
- Most rapid cognitive decline in APOE ε4 negative Alzheimer's disease with early onset (2009) (93)
- Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI (2012) (93)
- Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease (2018) (93)
- Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD (2003) (93)
- Impact of diagnostic disclosure in dementia on patients and carers: Qualitative case series analysis (2006) (93)
- Diagnostic impact of [18F]flutemetamol PET in early-onset dementia (2017) (92)
- Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment (2007) (92)
- Cerebral perfusion in the predementia stages of Alzheimer’s disease (2015) (92)
- Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma (2002) (92)
- Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers (2014) (90)
- Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology (2020) (90)
- Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease (2016) (90)
- The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease (2013) (90)
- Reliability and Sensitivity of Visual Scales versus Volumetry for Evaluating White Matter Hyperintensity Progression (2008) (89)
- Neuroimaging and Correlates of Cognitive Function among Patients with Heart Failure (2007) (89)
- Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease (2009) (88)
- Aducanumab: Appropriate Use Recommendations (2021) (88)
- Identifying confounds to increase specificity during a “no task condition” Evidence for hippocampal connectivity using fMRI (2003) (88)
- A new informant-based questionnaire for instrumental activities of daily living in dementia (2012) (88)
- The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis (2015) (88)
- Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials (2019) (87)
- Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment (2012) (87)
- A paced visual serial addition test for fMRI (2003) (87)
- Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer’s Disease (2008) (87)
- Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer’s disease (2019) (87)
- Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study (2008) (87)
- Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease (2016) (86)
- Incidence of cerebral microbleeds (2010) (86)
- Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment (2016) (86)
- Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment (2013) (86)
- Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease (2017) (85)
- Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. (2009) (85)
- Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2021) (85)
- The World of Dementia Beyond 2020 (2011) (85)
- Alzheimer's disease (2021) (85)
- Imaging of White Matter Lesions (2002) (85)
- Early-Onset Dementia Is Associated with Higher Mortality (2008) (85)
- Mild cognitive impairment with suspected nonamyloid pathology (SNAP) (2015) (85)
- Disruption of Functional Brain Networks in Alzheimer's Disease: What Can We Learn from Graph Spectral Analysis of Resting-State Magnetoencephalography? (2012) (85)
- On the Etiology of Incident Brain Lacunes: Longitudinal Observations From the LADIS Study (2008) (85)
- Role of white matter lesions in cognitive impairment of vascular origin. (1999) (85)
- Regional White Matter Integrity Differentiates Between Vascular Dementia and Alzheimer Disease (2009) (85)
- MRI volumetric correlates of white matter lesions in dementia with lewy bodies and Alzheimer's disease (2000) (84)
- Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease (2012) (84)
- Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study (2016) (83)
- The use of EEG in the diagnosis of dementia with Lewy bodies (2007) (83)
- Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease (2013) (82)
- Does a Family Meetings Intervention Prevent Depression and Anxiety in Family Caregivers of Dementia Patients? A Randomized Trial (2012) (82)
- Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes (2015) (82)
- Urinary Complaints in Nondisabled Elderly People with Age‐Related White Matter Changes: The Leukoaraiosis And DISability (LADIS) Study (2008) (82)
- Development of a Neuropsychological Battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): Experience and Baseline Data (2006) (82)
- CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. (2010) (81)
- Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy (2017) (81)
- Global Burden of Small Vessel Disease–Related Brain Changes on MRI Predicts Cognitive and Functional Decline (2019) (81)
- Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. (2018) (81)
- Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias (2000) (81)
- Increased cortical atrophy in patients with Alzheimer’s disease and type 2 diabetes mellitus (2005) (81)
- Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice (2014) (80)
- Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin? (2015) (79)
- Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results (2018) (79)
- Anterior Medial Temporal Lobe Activation during Attempted Retrieval of Encoded Visuospatial Scenes: An Event-Related fMRI Study (2001) (79)
- Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. (2016) (78)
- Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. (2003) (78)
- Discrepancy between subjective and objective sleep disturbances in early- and moderate-stage Alzheimer disease. (2012) (78)
- Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer’s Disease. An MEG Study with Virtual Electrodes (2016) (78)
- Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics (2015) (78)
- Trajectories of cognitive decline in different types of dementia (2014) (78)
- Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. (2012) (77)
- A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2019) (77)
- Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease. (2018) (77)
- Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old (2010) (77)
- Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration (2006) (77)
- Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer's disease and controls (2017) (76)
- Prevalence of cortical superficial siderosis in a memory clinic population (2014) (76)
- Vascular Care in Patients With Alzheimer Disease With Cerebrovascular Lesions Slows Progression of White Matter Lesions on MRI: The Evaluation of Vascular Care in Alzheimer's Disease (EVA) Study (2010) (76)
- BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. (2010) (76)
- Early diagnosis of dementia: neuroimaging (1999) (75)
- Apolipoprotein E ϵ4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias (1999) (75)
- Do Instrumental Activities of Daily Living Predict Dementia at 1‐ and 2‐Year Follow‐Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia Alzheimer's Disease Study (2011) (75)
- Differences in nutritional status between very mild Alzheimer's disease patients and healthy controls. (2014) (75)
- Cognitive Impairment in Alzheimer’s Disease Is Modified by APOE Genotype (2007) (74)
- Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum (2019) (74)
- EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects (2017) (74)
- Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases (2016) (74)
- Visual activation patterns in patients with optic neuritis (1998) (74)
- Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline (2018) (74)
- Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease (2009) (73)
- Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities (2008) (73)
- Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration (2003) (73)
- Microvascular disease in type 1 diabetes alters brain activation: a functional magnetic resonance imaging study. (2006) (73)
- Dementia: Alzheimer pathology and vascular factors: from mutually exclusive to interaction. (2012) (73)
- Neurological Signs in Relation to Type of Cerebrovascular Disease in Vascular Dementia (2008) (73)
- Magnetic resonance imaging predictors of cognition in mild cognitive impairment. (2007) (73)
- Corpus callosum size correlates with asymmetric performance on a dichotic listening task in healthy aging but not in Alzheimer's disease (2006) (72)
- Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study (2019) (72)
- Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. (2013) (72)
- Neurocardiovascular Instability, Hypotensive Episodes, and MRI Lesions in Neurodegenerative Dementia (2000) (72)
- International Work Group criteria for the diagnosis of Alzheimer disease. (2013) (72)
- Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease (2018) (72)
- Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe (2010) (71)
- Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study (2019) (71)
- Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project (2017) (71)
- Clinical significance of corpus callosum atrophy in a mixed elderly population (2007) (71)
- MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis (2017) (70)
- Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis (2017) (70)
- Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction (2006) (69)
- Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study (2013) (69)
- Pathological Aging of the Brain: An Overview (2004) (69)
- Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease (2013) (68)
- Resting-State Oscillatory Brain Dynamics in Alzheimer Disease (2008) (68)
- The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent (2012) (68)
- MRI and CT in the diagnosis of vascular dementia (2004) (67)
- Evaluation of Reference Regions for (R)-[11C]PK11195 Studies in Alzheimer's Disease and Mild Cognitive Impairment (2007) (67)
- Diffusion changes predict cognitive and functional outcome: The LADIS study (2013) (67)
- White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline (2015) (67)
- CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls (2007) (67)
- Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort (2011) (67)
- Receiving a diagnosis of dementia (2006) (67)
- A neural complexity measure applied to MEG data in Alzheimer's disease (2003) (66)
- The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics (2018) (66)
- How golden is the gold standard of neuropathology in dementia? (2011) (66)
- Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. (2000) (65)
- Prevention trials in Alzheimer's disease: An EU-US task force report (2011) (65)
- Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study (2017) (65)
- Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective (2020) (65)
- Imaging of static brain lesions in vascular dementia: implications for clinical trials. (1999) (65)
- Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? (2005) (64)
- Initial Complaints in Frontotemporal Lobar Degeneration (2004) (64)
- Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers (2012) (64)
- New insights on the genetic etiology of Alzheimer’s and related dementia (2020) (64)
- Comparison of International Working Group criteria and National Institute on Aging–Alzheimer’s Association criteria for Alzheimer’s disease (2012) (64)
- An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis (2004) (64)
- Visual assessment of medial temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry (1999) (63)
- Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change - The LADIS Study (2013) (63)
- Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease (2015) (63)
- Alzheimer’s disease: The state of the art in resting-state magnetoencephalography (2017) (63)
- Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. (2016) (63)
- Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic (2015) (62)
- Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions (2004) (62)
- Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease (2009) (62)
- Associations between Patterns of EEG Abnormalities and Diagnosis in a Large Memory Clinic Cohort (2008) (62)
- Efficacy of a medical food on cognition in Alzheimer’s Disease: Results from secondary analyses of a randomized, controlled trial (2011) (62)
- Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design (2017) (61)
- Validation of the Amsterdam IADL Questionnaire©, a New Tool to Measure Instrumental Activities of Daily Living in Dementia (2013) (61)
- Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease (2016) (61)
- Reproducibility of quantitative (R)-[11C]verapamil studies (2012) (60)
- L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients (2000) (60)
- ATN classification and clinical progression in subjective cognitive decline (2020) (60)
- Application of automated medial temporal lobe atrophy scale to Alzheimer disease. (2007) (60)
- Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts (2017) (59)
- Biomarker profiles and their relation to clinical variables in mild cognitive impairment (2005) (59)
- Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework (2017) (59)
- Cognitive reserve and clinical progression in Alzheimer disease (2019) (59)
- Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire (2016) (59)
- Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study (2018) (59)
- Blood-based metabolic signatures in Alzheimer's disease (2017) (58)
- Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future (2013) (58)
- Heterogeneity of Alzheimer’s disease: consequence for drug trials? (2018) (58)
- The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease (2014) (58)
- Imaging in Alzheimer's disease (2009) (58)
- Blood–brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene (2012) (58)
- Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. (2015) (57)
- White Matter Changes Contribute to Corpus Callosum Atrophy in the Elderly: The LADIS Study (2008) (57)
- New Research Criteria for the Diagnosis of Alzheimer’s Disease Applied in a Memory Clinic Population (2010) (57)
- Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. (2021) (57)
- Distinct perfusion patterns in Alzheimer’s disease, frontotemporal dementia and dementia with Lewy bodies (2014) (57)
- Loss of EEG Network Efficiency Is Related to Cognitive Impairment in Dementia With Lewy Bodies (2015) (57)
- A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort (2019) (57)
- Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease (2012) (56)
- The Diagnostic Value of Magnetic Resonance Imaging and Technetium 99m‐HMPAO Single‐Photon-Emission Computed Tomography for the Diagnosis of Alzheimer Disease in a Community‐Dwelling Elderly Population (1997) (56)
- Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light - a randomized clinical trial (2010) (55)
- Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population (2017) (55)
- Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease (2015) (55)
- [123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies (2016) (55)
- Psychiatric diagnoses underlying the phenocopy syndrome of behavioural variant frontotemporal dementia (2015) (55)
- Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation: ‘Last in–first out’ (2011) (54)
- Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. (2017) (54)
- Small vessel versus large vessel vascular dementia (2008) (54)
- Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. (2015) (54)
- BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease (2014) (54)
- CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. (2009) (54)
- Diabetes and cognitive impairment. Clinical diagnosis and brain imaging in patients attending a memory clinic. (2006) (54)
- Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study (2015) (53)
- Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease (2014) (53)
- Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images (2010) (53)
- Neuroanatomical and neuropsychological features of elderly euthymic depressed patients with early- and late-onset (2010) (53)
- Hippocampal Atrophy in Subcortical Vascular Dementia (2011) (53)
- Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort (2019) (53)
- Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
- Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. (2016) (52)
- Apolipoprotein E Genotype Influences Presence and Severity of Delusions and Aggressive Behavior in Alzheimer Disease (2006) (52)
- Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects (2000) (52)
- The Use of MRI and PET for Clinical Diagnosis of Dementia and Investigation of Cognitive Impairment : A Consensus Report (2004) (52)
- The role of the orbitofrontal cortex in cognition and behavior (2015) (52)
- White Matter Lesions Are Associated With Progression of Medial Temporal Lobe Atrophy in Alzheimer Disease (2006) (52)
- Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. (1997) (51)
- Transcranial Doppler blood flow assessment in patients with mild heart failure: correlates with neuroimaging and cognitive performance. (2008) (51)
- The transmethylation cycle in the brain of Alzheimer patients (2005) (51)
- Vascular dementia: the role of cerebral infarcts. (1999) (51)
- Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer’s Disease (2014) (51)
- Comparison of the Alzheimer’s Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in Differentiating Elderly Individuals with Different Degrees of White Matter Changes (2007) (51)
- Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews (2013) (51)
- Prevalence and Clinical Significance of Epileptiform EEG Discharges in a Large Memory Clinic Cohort (2010) (51)
- Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions (2014) (51)
- Clinical Symptoms and Risk Factors in Cerebral Microangiopathy Patients (2013) (50)
- Progression of Alzheimer disease in Europe: data from the European ICTUS study. (2012) (50)
- Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration (2008) (50)
- The effect of APOE genotype on clinical phenotype in Alzheimer disease (2006) (50)
- Gray matter network disruptions and amyloid beta in cognitively normal adults (2016) (50)
- A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease (2017) (50)
- Leuko-Araiosis: Relationship with the Types of Focal Lesions Occurring in Acute Cerebrovascular Disorders (1992) (50)
- European Pentoxifylline Multi-Infarct Dementia Study. (1996) (50)
- PLD3 variants in population studies (2015) (49)
- The influence of coincidental vascular pathology on symptomatology and course of Alzheimer's disease. (1998) (49)
- Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? (2019) (49)
- Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. (2017) (49)
- Reproducibility of EEG functional connectivity in Alzheimer’s disease (2020) (48)
- Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics (2019) (48)
- Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy (1994) (48)
- Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease (2015) (48)
- The role of white matter hyperintensities and medial temporal lobe atrophy in age-related executive dysfunctioning (2008) (48)
- White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients. (2011) (48)
- Blood pressure and progression of brain atrophy: the SMART-MR Study. (2013) (48)
- Microbleeds do not affect rate of cognitive decline in Alzheimer's disease (2011) (48)
- MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study (2018) (48)
- Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study (1999) (48)
- Parametric fMRI analysis of visual encoding in the human medial temporal lobe (1999) (48)
- Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes (2007) (47)
- Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. (2016) (47)
- EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls (2016) (47)
- Frontal lobe dysfunction in unilateral lenticulostriate infarcts. Prominent role of cortical lesions. (1992) (47)
- The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description (2018) (47)
- Attention modulates hemispheric differences in functional connectivity: Evidence from MEG recordings (2006) (47)
- Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline (2016) (47)
- EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity (2010) (46)
- A clinical-radiological framework of the right temporal variant of frontotemporal dementia (2020) (46)
- Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics (2014) (46)
- Hippocampal sulcus width and cavities: comparison between patients with Alzheimer disease and nondemented elderly subjects. (2006) (46)
- Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics (2012) (46)
- A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. (2016) (46)
- Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer’s disease pathology (2016) (46)
- Assessment of Instrumental Activities of Daily Living in Dementia (2013) (45)
- White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study (2009) (45)
- More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer's disease. (2015) (45)
- Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains (2015) (45)
- CSF tau and Aβ42 are not useful in the diagnosis of frontotemporal lobar degeneration (2004) (44)
- Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. (2015) (44)
- Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the Sunnybrook Dementia Study. (2011) (44)
- Diagnostic Accuracy of Consensus Diagnostic Criteria for Frontotemporal Dementia in a Memory Clinic Population (2008) (44)
- Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration (2007) (44)
- A case of progressive aphasia without dementia: "temporal" Pick's disease? (1990) (44)
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
- Head trauma and Alzheimer's disease. (2002) (44)
- Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline (2020) (44)
- Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study (2013) (44)
- Thalamic Lesions in Vascular Dementia: Low Sensitivity of Fluid-Attenuated Inversion Recovery (FLAIR) Imaging (2004) (44)
- Applying the ATN scheme in a memory clinic population (2019) (44)
- Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic (2010) (44)
- Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. (2015) (43)
- Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk (2019) (43)
- Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. (1997) (43)
- Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment (2009) (43)
- The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium (2008) (42)
- Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease (2016) (42)
- Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden. (2015) (42)
- Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers (2013) (42)
- Sleep apnea syndrome presenting with cognitive impairment (1991) (42)
- Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years (2018) (42)
- The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia (2011) (42)
- Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. (2008) (42)
- Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease (2018) (42)
- Dementia: the bare essentials. (2009) (42)
- Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population (2017) (42)
- Interindividual differences of medial temporal lobe activation during encoding in an elderly population studied by fMRI (2004) (41)
- SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. (2014) (41)
- Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer’s disease (2007) (41)
- Assessing Amyloid Pathology in Cognitively Normal Subjects Using 18F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods (2018) (41)
- How Useful Is the IQCODE for Discriminating between Alzheimer’s Disease, Mild Cognitive Impairment and Subjective Memory Complaints? (2010) (41)
- Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme control analysis of Alzheimer’s disease (2018) (41)
- Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. (2012) (41)
- A new rapid landmark-based regional MRI segmentation method of the brain (2002) (40)
- Quantification of Tau Load Using [18F]AV1451 PET (2017) (40)
- Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease (2016) (40)
- Functional connectivity in elderly controls and AD patients using resting state fMRI: a pilot study. (2005) (40)
- Raloxifene affects brain activation patterns in postmenopausal women during visual encoding. (2001) (40)
- Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. (2018) (40)
- The Added Value of 18-Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of the Behavioral Variant of Frontotemporal Dementia (2014) (40)
- Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study (2015) (40)
- Amyloid and its association with default network integrity in Alzheimer's disease (2014) (40)
- Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline (2017) (40)
- Multitracer model for staging cortical amyloid deposition using PET imaging (2020) (39)
- Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease. (2015) (39)
- Neuroanatomical and neuropsychological features of euthymic patients with bipolar disorder. (2009) (39)
- Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAAS (2010) (39)
- Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis (1994) (39)
- Development of quality indicators for memory clinics (2008) (39)
- Early-onset Alzheimer's disease is associated with a distinct neuropsychological profile (2011) (39)
- Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. (1997) (39)
- Visual rating of hippocampal atrophy: correlation with volumetry. (1994) (39)
- Evaluation of Methods for Generating Parametric (R)-[11C]PK11195 Binding Images (2007) (39)
- Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment (2016) (39)
- Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging (2017) (39)
- Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease (2016) (38)
- A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease (2017) (38)
- Sporadic Creutzfeldt‐Jakob disease in a young Dutch valine homozygote: Atypical molecular phenotype (2001) (38)
- Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease (2016) (38)
- Pathologic findings in a case of primary progressive aphasia (1994) (38)
- CSF markers related to pathogenetic mechanisms in Alzheimer's disease (2002) (38)
- The sensitivity to change over time of the Amsterdam IADL Questionnaire© (2013) (38)
- Evidence for atrophy of the corpus callosum in Alzheimer's disease. (1994) (38)
- (Cost)-effectiveness of family meetings on indicated prevention of anxiety and depressive symptoms and disorders of primary family caregivers of patients with dementia: design of a randomized controlled trial (2008) (38)
- Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion‐weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the elderly) study (2009) (38)
- ABCA7 p.G215S as potential protective factor for Alzheimer's disease (2016) (38)
- EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology (2018) (38)
- Genetic and biochemical markers for Alzheimer's disease: recent developments (2000) (38)
- Physical activity and white matter lesion progression (2007) (38)
- Identifying target groups for the prevention of depression among caregivers of dementia patients (2011) (38)
- Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease (2008) (38)
- The EMIF-AD PreclinAD study: study design and baseline cohort overview (2018) (37)
- Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. (2017) (37)
- Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project (2019) (37)
- ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease (2021) (37)
- Distribution of APOE Genotypes in a Memory Clinic Cohort (2008) (36)
- 7T T2 ∗-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease (2015) (36)
- Secondary prevention of Alzheimer’s dementia: neuroimaging contributions (2018) (36)
- Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. (2017) (36)
- Preliminary Results from an MRI/CT‐Based Database for Vascular Dementia and Alzheimer's Disease (2000) (36)
- A nutritional approach to ameliorate altered phospholipid metabolism in Alzheimer's disease. (2014) (36)
- Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. (2015) (36)
- Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. (2018) (36)
- Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay (2019) (35)
- Medial temporal lobe atrophy in an open population of very old persons (1995) (35)
- Decreased cerebrospinal fluid amyloid beta (1–40) levels in frontotemporal lobar degeneration (2006) (35)
- Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease (2015) (35)
- Gray matter network measures are associated with cognitive decline in mild cognitive impairment (2018) (34)
- Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study. (2014) (34)
- Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease (2014) (34)
- Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease (2008) (34)
- PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment (2020) (34)
- Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: Secondary analyses from a randomized, controlled trial (2011) (34)
- Progression of cerebral white matter lesions in Alzheimer’s disease: a new window for therapy? (2005) (34)
- An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease (2018) (34)
- PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment (2020) (34)
- The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases (2015) (34)
- Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study (2013) (34)
- Apraxia in Mild Cognitive Impairment and Alzheimer's Disease: Validity and Reliability of the Van Heugten Test for Apraxia (2014) (34)
- Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. (1999) (34)
- Diabetes and cognitive impairment (2006) (34)
- Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation (2016) (34)
- Quantitative regional validation of the visual rating scale for posterior cortical atrophy (2014) (33)
- [Development of memory clinics in The Netherlands]. (2007) (33)
- Raloxifene Treatment Enhances Brain Activation during Recognition of Familiar Items: a Pharmacological fMRI Study in Healthy Elderly Males (2006) (33)
- EEG functional connectivity and ApoE genotype in Alzheimer’s disease and controls (2008) (33)
- The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study (2014) (33)
- Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid (2002) (33)
- Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers (2021) (33)
- Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies (2020) (33)
- Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease (2018) (33)
- Whole brain analysis of T2* weighted baseline FMRI signal in dementia (2007) (33)
- Cerebrospinal fluid levels of Alzheimer’s disease biomarkers in middle-aged patients with type 1 diabetes (2014) (33)
- Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression (2019) (33)
- Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset (2019) (33)
- Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior (2005) (33)
- An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion (2013) (33)
- Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease (2014) (32)
- Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies (2009) (32)
- Diagnosing Alzheimer's disease in community-dwelling elderly: a comparison of EEG and MRI. (1997) (32)
- Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the “Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment” (TRACE-VCI) Study (2017) (32)
- Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care) (2017) (32)
- A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline (2018) (32)
- Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders (2017) (32)
- Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study (2017) (32)
- Discordant amyloid-β PET and CSF biomarkers and its clinical consequences (2019) (32)
- The structure of the geriatric depressed brain and response to electroconvulsive therapy (2014) (32)
- SPM analysis of parametric (R)-[11C]PK11195 binding images: Plasma input versus reference tissue parametric methods (2007) (32)
- Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype (2020) (32)
- Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome (2016) (31)
- Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort (2021) (31)
- Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease (2019) (31)
- Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project (2019) (31)
- Blood Pressure, White Matter Lesions and Medial Temporal Lobe Atrophy: Closing the Gap between Vascular Pathology and Alzheimer’s Disease? (2005) (31)
- The renin-angiotensin-aldosterone system in cerebral small vessel disease (2008) (31)
- Can we do better in developing new drugs for Alzheimer's disease? (2009) (30)
- Normal cerebrospinal fluid glutathione concentrations in Parkinson’s disease, Alzheimer’s disease and multiple system atrophy (1999) (30)
- Medial Temporal Lobe Atrophy and APOE Genotype Do Not Predict Cognitive Improvement upon Treatment with Rivastigmine in Alzheimer’s Disease Patients (2005) (30)
- Alzheimer’s disease—one clinical syndrome, two radiological expressions: a study on blood pressure (2004) (30)
- MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment (2017) (30)
- Infratentorial Abnormalities in Vascular Dementia (2006) (30)
- The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial (2013) (30)
- A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers (2018) (30)
- Diagnostic and economic evaluation of new biomarkers for Alzheimer’s disease: the research protocol of a prospective cohort study (2012) (30)
- Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores (2019) (30)
- Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer’s disease correlates with pathology (2014) (30)
- No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy (2014) (30)
- Angiotropic intravascular large-cell lymphoma with massive cerebral extension. (1993) (29)
- Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology (2015) (29)
- The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease (2015) (29)
- Arterial stiffness and progression of structural brain changes (2015) (29)
- Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2017) (29)
- Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. (2016) (29)
- Pain intensity and pain affect in relation to white matter changes (2006) (29)
- Early diagnostic indices for the prevention of Alzheimer's disease. (1998) (29)
- Neuropathology and cognitive performance in self-reported cognitively healthy centenarians (2018) (29)
- Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review (2018) (28)
- Brain imaging and Alzheimer's disease (1993) (28)
- A 24-year follow-up of body mass index and cerebral atrophy (2005) (28)
- Clinically silent dysfunction of dorsal columns and dorsal spinocerebellar tracts in hereditary spastic paraparesis (1994) (28)
- Auditory hallucinations in adults with hearing impairment: a large prevalence study (2018) (28)
- Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project (2019) (28)
- White matter hyperintensities and cognitive impairment during electroconvulsive therapy in severely depressed elderly patients. (2014) (28)
- Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset (2019) (28)
- The plasma peptides of ovarian cancer (2018) (28)
- Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease (2019) (28)
- Dementia and Rapid Mortality: Who is at Risk? (2016) (28)
- Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers (2017) (28)
- Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Non-Pain Related Cognitive and Behavioural Functioning (2002) (28)
- Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults (2018) (28)
- Gut Microbiota Composition Is Related to AD Pathology (2022) (28)
- A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study (2017) (27)
- Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy (2018) (27)
- The Rest-Activity Rhythm and Physical Activity in Early-Onset Dementia (2015) (27)
- Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs (2017) (27)
- Quantification of [18F]florbetapir: A test–retest tracer kinetic modelling study (2018) (27)
- Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project (2020) (27)
- [Slowly progressive aphasia without dementia]. (1991) (27)
- Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study (2013) (27)
- Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders. (2018) (27)
- Moving forward with nutrition in Alzheimer’s disease (2009) (27)
- The impact of diagnostic disclosure in dementia: a qualitative case analysis (2005) (27)
- Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. (2011) (27)
- Research Criteria for the Behavioral Variant of Alzheimer Disease (2021) (27)
- AMYPAD Diagnostic and Patient Management Study: Rationale and design (2018) (27)
- The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. (2017) (26)
- Small Infarcts in the Centrum ovale: Study of Predisposing Factors (1994) (26)
- Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum (2019) (26)
- Dementia Mimicking Alzheimer's Disease Owing to a Tau Mutation: CSF and PET Findings (2010) (26)
- Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. (2013) (26)
- Low Prevalence of Mixed Dementia in a Cohort of 2,000 Elderly Patients in a Memory Clinic Setting. (2016) (26)
- Corpus Callosum Tissue Loss and Development of Motor and Global Cognitive Impairment: The LADIS Study (2012) (26)
- Vascular dementia: the role of cerebral infarcts (1999) (26)
- Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease (2018) (26)
- Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions (2019) (26)
- Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease (2020) (26)
- Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index. (2015) (26)
- Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer's disease with the use of index values. (2011) (26)
- Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result (2018) (26)
- Assessing Fitness to Drive in Patients With Different Types of Dementia (2017) (26)
- Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia (2012) (25)
- Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity (2016) (25)
- Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples (2011) (25)
- Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project (2019) (25)
- In vivo tau pathology is associated with synaptic loss and altered synaptic function (2021) (25)
- A Dutch family with autosomal dominant pure spastic paraparesis (Strümpell's disease) (1990) (25)
- Effectiveness of Family Meetings for Family Caregivers on Delaying Time to Nursing Home Placement of Dementia Patients: A Randomized Trial (2012) (25)
- Quantification of amyloid-beta 40 in cerebrospinal fluid. (2009) (25)
- Comparison of Simplified Parametric Methods for Visual Interpretation of 11C-Pittsburgh Compound-B PET Images (2014) (25)
- Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease (2018) (25)
- SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network (2021) (25)
- Distortions in rest–activity rhythm in aging relate to white matter hyperintensities (2008) (24)
- Neuroimaging in Dementia (2011) (24)
- The frequency and influence of dementia risk factors in prodromal Alzheimer's disease (2017) (24)
- Clinical Characteristics of Patients With Frontotemporal Dementia With and Without Lobar Atrophy on MRI (2010) (24)
- Progression to dementia in memory clinic patients without dementia (2013) (24)
- Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology (2018) (24)
- Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey (2019) (24)
- Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease (2019) (24)
- The effect of anxiety and depression on decline of memory function in Alzheimer's disease (2009) (24)
- A prediction model to calculate probability of Alzheimer’s disease using cerebrospinal fluid biomarkers (2013) (24)
- Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier (2018) (24)
- Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease. (2010) (24)
- Alzheimer disease: Hippocampal volume loss and Alzheimer disease progression (2009) (24)
- Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease (2019) (24)
- Validation of the HIV Dementia Scale in an Elderly Cohort of Patients with Subcortical Cognitive Impairment Caused by Subcortical Ischaemic Vascular Disease or a Normal Pressure Hydrocephalus (2004) (24)
- Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia (2012) (24)
- Neuro-imaging in the diagnosis of Alzheimer's disease I. Computer tomography and magnetic resonance imaging (1992) (23)
- Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment (2017) (23)
- LOW VITAMIN B6 LEVELS ARE ASSOCIATED WITH WHITE MATTER LESIONS IN ALZHEIMER'S DISEASE (2005) (23)
- Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory (2018) (23)
- Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease (2019) (23)
- Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. (2015) (23)
- Assessing fitness to drive—A validation study on patients with mild cognitive impairment (2017) (23)
- Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia (2017) (23)
- Disrupted subject‐specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy (2016) (23)
- A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease (2021) (23)
- Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6 (2021) (23)
- Cognitive Impairment No Dementia – Neuropsychological and Neuroimaging Characterization of an Amnestic Subgroup (2008) (23)
- Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide (2013) (23)
- Is the whole brain periventricular? (2006) (23)
- Associations between magnetic resonance imaging measures and neuropsychological impairment in early and late onset alzheimer's disease. (2013) (23)
- White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study (2019) (23)
- DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. (2015) (22)
- Magnetic resonance imaging in dementia (2004) (22)
- Neuro-imaging in the diagnosis of Alzheimer's disease II. Positron and single photon emission tomography (1993) (22)
- Shifting Paradigms in Dementia (2007) (22)
- White Matter Hyperintensities and Working Memory: An Explorative Study (2008) (22)
- The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial (2014) (21)
- The metabolic syndrome in a memory clinic population: Relation with clinical profile and prognosis (2015) (21)
- Fingerprinting Alzheimer's Disease by 1H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. (2020) (21)
- Utility of imaging for nutritional intervention studies in Alzheimer's disease. (2011) (21)
- “Alzheimer's disease” is neither “Alzheimer's clinical syndrome” nor “dementia” (2019) (21)
- Regional Differences in Effects of APOE ε4 on Cognitive Impairment in Non-Demented Subjects (2011) (21)
- Alzheimer's disease patients not carrying the apolipoprotein E ε4 allele show more severe slowing of oscillatory brain activity (2013) (21)
- Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease (2018) (21)
- CSF ApoE predicts clinical progression in nondemented APOEε4 carriers (2017) (21)
- EEG Abnormalities Are Associated with Different Cognitive Profiles in Alzheimer’s Disease (2010) (21)
- CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging (2006) (21)
- Data‐driven approaches for tau‐PET imaging biomarkers in Alzheimer's disease (2018) (21)
- Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease (2019) (21)
- Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease (2020) (21)
- European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials (2018) (21)
- Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients (2017) (21)
- Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab (2018) (21)
- The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease (2016) (20)
- Clinician-patient communication during the diagnostic workup: The ABIDE project (2019) (20)
- rCBF SPECT in Parkinson's disease patients with mental dysfunction. (1997) (20)
- Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline (2020) (20)
- A paradoxical relationship (20)
- Longitudinal Maintenance of Cognitive Health in Centenarians in the 100-plus Study (2020) (20)
- PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases (2019) (20)
- Evaluating combinations of diagnostic tests to discriminate different dementia types (2018) (20)
- Cooperation and Networking on White Matter Disorders: The European Task Force on Age-Related White Matter Changes (1998) (20)
- Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies (2020) (20)
- Rating scale for age related brain changes (2000) (20)
- Efficacy and safety of gantenerumab in prodromal Alzheimer’s disease: Results from scarlet road—a global, multicenter trial (2015) (20)
- EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies (2018) (20)
- Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals (2018) (20)
- Functional MRI of visual cortex in sedated 18 month-old infants with or without periventricular leukomalacia. (2001) (20)
- Use of laboratory and imaging investigations in dementia (2005) (19)
- APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease (2020) (19)
- A four-generation Dutch family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), linked to chromosome 19p13 (1995) (19)
- Study protocol: EXERcise and Cognition In Sedentary adults with Early-ONset dementia (EXERCISE-ON) (2012) (19)
- Validation of soluble amyloid‐β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases (2016) (19)
- Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6 (2021) (19)
- Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements (2008) (19)
- Alzheimer's Disease and Other Disorders Associated With Dementia (2008) (19)
- A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus (2018) (19)
- Revised research diagnostic criteria for Alzheimer's disease (2008) (19)
- Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia (2013) (19)
- The plasma peptidome (2018) (19)
- Progressive dementia and mesiotemporal atrophy on brain MRI: Neurosyphilis mimicking pre‐senile Alzheimer’s disease? (2007) (19)
- Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study (2014) (19)
- Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer’s Disease (2020) (19)
- Exercise and Early-Onset Alzheimer's Disease: Theoretical Considerations (2012) (19)
- Psychosis in behavioral variant frontotemporal dementia (2017) (19)
- Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity (2021) (19)
- 2001-2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease? (2011) (19)
- A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging (2017) (19)
- Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study (2014) (19)
- The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome: Clinical Predictors for Primary Psychiatric Disorders Versus Behavioral Variant Frontotemporal Dementia. (2017) (18)
- Multiple diagnostic tests are needed to assess multiple causes of dementia. (2006) (18)
- The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design (2017) (18)
- Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study (2020) (18)
- Diagnostic Criteria for Vascular Dementia (1998) (18)
- Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study (2018) (18)
- Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ε4 carriers. (2013) (18)
- The Alzheimer’s disease drug development landscape (2021) (18)
- Structural neuroimaging of Alzheimer’s disease and other dementias (2001) (18)
- Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease–specific regions (2019) (18)
- Cognitive Deficits in Patients With Neuropsychiatric Symptoms: A Comparative Study Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. (2017) (18)
- White‐matter lesions on CT in Alzheimer patients (1991) (18)
- Progression from MCI to AD: Predictive value of CSF Aβ42 is modified by APOE genotype (2011) (18)
- Automatically computed rating scales from MRI for patients with cognitive disorders (2019) (18)
- Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias (2020) (18)
- Can novel therapeutics halt the amyloid cascade? (2010) (18)
- Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease (2018) (17)
- Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life (2015) (17)
- Performance of a modified supervised cluster algorithm for extracting reference region input functions from (R)-[11C]PK11195 brain PET studies (2008) (17)
- Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects (2017) (17)
- Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort (2019) (17)
- Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. (2014) (17)
- Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders. (2006) (17)
- Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline (2022) (17)
- Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease (2020) (17)
- Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers (2013) (17)
- Improving the Accuracy and Precision of Cognitive Testing in Mild Dementia (2011) (17)
- Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia (2018) (17)
- Diagnostic tools for the study of vascular cognitive dysfunction in hypertension and antihypertensive drug research. (2006) (17)
- A model for disclosure of the diagnosis of dementia (2006) (17)
- Survival in memory clinic cohort is short, even in young-onset dementia (2018) (17)
- Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline (2021) (17)
- Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts (2021) (17)
- Pre- and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer's disease (1993) (17)
- The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries (2019) (17)
- Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status (2021) (17)
- Re-evaluation of cerebrospinal fluid angiotensin-converting enzyme activity in patients with 'probable' Alzheimer's disease. (1993) (16)
- Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. (2020) (16)
- In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer’s disease (2019) (16)
- Disorders Primarily Affecting White Matter (2002) (16)
- Intravenous immunoglobulins: a treatment for Alzheimer’s disease? (2004) (16)
- A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility (2017) (16)
- Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic (2018) (16)
- Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies (2019) (16)
- Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 (2021) (16)
- A Suboptimal Diet Is Associated with Poorer Cognition: The NUDAD Project (2020) (16)
- Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. (2015) (15)
- The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. (2016) (15)
- White matter hyperintensities and vascular risk factors in monozygotic twins (2018) (15)
- Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease (2019) (15)
- Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results (2021) (15)
- No Evidence for Additional Blood–Brain Barrier P-Glycoprotein Dysfunction in Alzheimer's Disease Patients with Microbleeds (2012) (15)
- Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. (2022) (15)
- Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project (2019) (15)
- 2017 NIA-AA RESEARCH FRAMEWORK TO INVESTIGATE THE ALZHEIMER’S DISEASE CONTINUUM (2017) (15)
- Can post-mortem MRI be used as a proxy for in vivo? A case study (2019) (15)
- Cerebrospinal fluid tau levels in frontotemporal dementia (2005) (15)
- Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: the NUDAD project (2020) (15)
- The natural history of primary progressive aphasia: beyond aphasia (2021) (15)
- Association of amyloid-β CSF/PET discordance and tau load 5 years later (2020) (15)
- Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An 123I-FP-CIT SPECT study (2019) (15)
- Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100‐Plus Study (2018) (14)
- A Case of Macrocephaly, Hydrocephalus, Megacerebellum, White Matter Abnormalities and Rosenthal Fibres (1993) (14)
- Cortical phase changes measured using 7‐T MRI in subjects with subjective cognitive impairment, and their association with cognitive function (2016) (14)
- Tenth Meeting of the European Neurological Society 18–22 June, 2000, Jerusalem, Israël (2000) (14)
- Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum (2021) (14)
- Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. (2015) (14)
- Lumbar puncture in patients with neurologic conditions (2017) (14)
- Clinical neurophysiology in the diagnosis of Alzheimer's disease (1994) (14)
- Parametric methods for [18F]flortaucipir PET (2018) (14)
- Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. (2015) (14)
- Associations Between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review (2020) (14)
- White-Matter Changes on MRI as Surrogate Marker (2003) (14)
- Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project (2019) (14)
- Olfactory and gustatory functioning and food preferences of patients with Alzheimer’s disease and mild cognitive impairment compared to controls: the NUDAD project (2019) (14)
- Dutch Brain Research Registry for study participant recruitment: Design and first results (2021) (14)
- Computer-assisted prediction of clinical progression in the earliest stages of AD (2018) (14)
- Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort (2020) (14)
- A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands (2016) (14)
- High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline (2019) (13)
- Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) (13)
- Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. (2016) (13)
- Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review (2020) (13)
- A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study (2021) (13)
- Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study (2019) (13)
- Amyloid‐β PET and CSF in an autopsy‐confirmed cohort (2020) (13)
- Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study (2019) (13)
- Protocols for cognitive enhancement. A user manual for Brain Health Services—part 5 of 6 (2021) (13)
- Meningeal Gd-DTPA enhancement in multiple sclerosis. (1992) (13)
- Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease (2020) (13)
- Correction: Single-Subject Grey Matter Graphs in Alzheimer's Disease (2013) (13)
- Subcortical white matter pathology as a mediating factor for age-related decreased performance in dichotic listening (2007) (13)
- Serum α1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease (1993) (13)
- Functional MRI of visual cortex in sedated 18 month‐old infants with or without periventricular leukomalacia (2001) (13)
- Relationships between white matter hyperintensities, cerebral amyloid angiopathy and dementia in a population-based sample of the oldest old. (2013) (13)
- Increased skin temperature in Alzheimer’s disease is associated with sleepiness (2012) (13)
- Education as Proxy for Cognitive Reserve in a Large Elderly Memory Clinic: 'Window of Benefit'. (2020) (13)
- Latent atrophy factors related to phenotypical variants of posterior cortical atrophy (2020) (13)
- Medial temporal lobe atrophy scores translated to clinical practice: Editorial comment on ‘Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut‐offs' (2014) (13)
- ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly (2019) (13)
- Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies (2020) (13)
- White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease (2017) (13)
- The Auditory Oddball Paradigm in Patients with Vascular Cognitive Impairment: A Prolonged Latency of the N2 Complex (2006) (13)
- Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status (2020) (12)
- Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment (2010) (12)
- The Cognitive‐Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch‐Cog study cohort (2020) (12)
- Imaging biomarkers in Alzheimer's disease: added value in the clinical setting. (2017) (12)
- Methotrexate induced brain necrosis and severe leukoencephalopathy due to disconnection of an Ommaya device (1993) (12)
- ASSOCIATION BETWEEN VITAMIN B6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM (2007) (12)
- Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. (2018) (12)
- The plasma peptides of breast versus ovarian cancer (2019) (12)
- Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent (2021) (12)
- The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. (2019) (12)
- Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. (1992) (12)
- Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders. (2019) (12)
- The effects of age and Alzheimer’s disease on hippocampal volumes, a MRI study (2005) (12)
- Schizophrenia as a mimic of behavioral variant frontotemporal dementia (2016) (12)
- Peripheral electrical nerve stimulation and rest‐activity rhythm in Alzheimer's disease (2006) (11)
- Re-aligning scientific and lay narratives of Alzheimer's disease (2019) (11)
- Nonlinear Changes in Brain Activity During Continuous Word Repetition: An Event-Related Multiparametric Functional MR Imaging Study (2007) (11)
- Onset of Preclinical Alzheimer Disease in Monozygotic Twins (2021) (11)
- Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings (2020) (11)
- Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort (2015) (11)
- No evidence for increased self‐reported cognitive failure in Type 1 and Type 2 diabetes: a cross‐sectional study (2007) (11)
- Early life involvement in C9orf72 repeat expansion carriers (2021) (11)
- Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort (2014) (11)
- Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease (2020) (11)
- Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (11)
- The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer’s disease (2014) (11)
- Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum (2020) (11)
- Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease (2015) (11)
- The plasma peptides of Alzheimer’s disease (2021) (10)
- Neuropsychiatric and cognitive symptoms across the Alzheimer's disease clinical spectrum: Cross-sectional and longitudinal associations (2021) (10)
- Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. (2017) (10)
- Joint Effect Of Hypertension And Apoe Genotype On CSF Biomarkers For Alzheimer's Disease (2009) (10)
- Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
- Magnetoencephalography for the Detection of Intervention Effects of a Specific Nutrient Combination in Patients with Mild Alzheimer’s Disease: Results from an Exploratory Double-Blind, Randomized, Controlled Study (2016) (10)
- White matter microstructure disruption in early stage amyloid pathology (2021) (10)
- Intracerebral haemorrhage in Sneddon's syndrome (1992) (10)
- Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review (2021) (10)
- Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis (2013) (10)
- Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers (2022) (10)
- Progressive, isolated language disturbance: Its significance in a 65-year-old-man. A case report with implications for treatment and review of literature (2006) (10)
- Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis? (2021) (10)
- Dementia risk communication. A user manual for Brain Health Services—part 3 of 6 (2021) (10)
- SUCLG 2 identified as both a determinator of CSF A b 1 – 42 levels and an attenuator of cognitive decline in Alzheimer ’ s disease (2014) (10)
- Most rapid cognitive decline in APOE4 negative Alzheimer's disease with early onset (2009) (10)
- Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score (2021) (10)
- Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers (2017) (9)
- Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid (2020) (9)
- Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid. (2005) (9)
- The association between APOE ε4 and Alzheimer-type dementia among memory clinic patients is confined to those with a higher education. The DESCRIPA Study. (2013) (9)
- Assessment of microglial activation in mild cognitive impairment using [11C](R)-PK11195 and PET (2006) (9)
- An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence (2018) (9)
- Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer’s Disease – Data from the ICTUS Study (2008) (9)
- Cognitive and functional progression of dementia in two longitudinal studies (2019) (9)
- A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation (2016) (9)
- Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data (2009) (9)
- Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. (2006) (9)
- TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels (2021) (9)
- Frontotemporal dementia, music perception and social cognition share neurobiological circuits: A meta-analysis (2021) (9)
- Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI (2020) (9)
- Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study (2020) (9)
- Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. (2020) (9)
- Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment: the effect of age at onset (2019) (9)
- Dementia in 2011: Microbleeds in dementia—singing a different ARIA (2012) (9)
- [Cerebral white matter lesions in the elderly: vascular risk factors and cognitive consequences]. (2002) (9)
- Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population. (2018) (9)
- Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project (2020) (9)
- Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease (2020) (8)
- Simplified parametric methods for [18F]FDDNP studies (2010) (8)
- Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes (2021) (8)
- CSF levels of PSA and PSA–ACT complexes in Alzheimer's disease (2009) (8)
- Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer’s disease subgroups (2021) (8)
- Peripheral Electrical Stimulation in Alzheimer’s Disease (2005) (8)
- Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum (2020) (8)
- The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series (2021) (8)
- [18F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers (2021) (8)
- IEEE Nuclear Science Symposium Conference Record, 2008. NSS '08 (2009) (8)
- Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review (2021) (8)
- Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic (2010) (8)
- Magnetic Resonance Imaging Hyperintensities in Alzheimer's Disease-Reply (1991) (8)
- Kinetics and 28-day test–retest repeatability and reproducibility of [11C]UCB-J PET brain imaging (2020) (8)
- Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. (2017) (8)
- Spatial-Temporal Patterns of β-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis. (2022) (8)
- Added value of amyloid PET in individualized risk predictions for MCI patients (2019) (8)
- MicroRNA Analysis in the Spinal Fluid of Alzheimer Patients: A Methodological Feasibility Study (2010) (8)
- THE BARE ESSENTIALS (2009) (8)
- What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force (2018) (8)
- IN PURSUIT OF A SENSITIVE EEG FUNCTIONAL CONNECTIVITY OUTCOME MEASURE FOR CLINICAL TRIALS IN ALZHEIMER’S DISEASE (2019) (8)
- NEUROPATHOLOGICAL HALLMARKS OF ALZHEIMER’S DISEASE IN POSTMORTEM AD RETINAS (2018) (8)
- An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels (2010) (8)
- Replication study of plasma proteins relating to Alzheimer's pathology (2021) (8)
- Effects of High-Frequency Cranial Electrostimulation on the Rest-Activity Rhythm and Salivary Cortisol in Alzheimer’s Disease (2006) (8)
- Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and cerebrospinal fluid biomarkers (2013) (7)
- Use of proteomic approaches to identify disease biomarkers (2007) (7)
- Amyloid- (cid:1) (1– 42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease (2009) (7)
- Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort (2021) (7)
- Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study (2019) (7)
- Framework : Toward a Biological Definition of Alzheimer ' s Disease (2018) (7)
- Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. (2016) (7)
- Evaluation of plasma A40 and A42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment (2010) (7)
- as potential protective factor for Alzheimer’s disease (2016) (7)
- Autosomal recessive paraparesis with amyotrophy of the hands and feet (1993) (7)
- Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment. (2016) (7)
- Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review (2017) (7)
- Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review (2022) (7)
- Microbleeds are associated with depressive symptoms in Alzheimer's disease (2017) (7)
- P2-158 Effect of galantamine treatment on brain atrophy as assessed by MRI in patients with mild cognitive impairment (2004) (7)
- Featured Article Cerebrospinal fluid Ab42 is the best predictor of clinical progression in patients with subjective complaints (2013) (7)
- Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal (2019) (7)
- Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD (2021) (7)
- P4-392: The efficacy of souvenaid™ in mild Alzheimer's disease: Design of a randomized, controlled, double-blind, parallel group, multicentre, multicountry clinical trial (2008) (7)
- cCOG: A web‐based cognitive test tool for detecting neurodegenerative disorders (2020) (6)
- DURATION OF ALZHEIMER’S DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTI-STATE MODEL ANALYSIS (2017) (6)
- Prediction of poor clinical outcome in vascular cognitive impairment: TRACE‐VCI study (2020) (6)
- P1-388: Resting-state oscillatory brain dynamics in Alzheimer's disease (2008) (6)
- Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy (2020) (6)
- Combinations of Service Use Types of People With Early Cognitive Disorders. (2016) (6)
- How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. (2019) (6)
- Molecular markers of Alzheimer's Disease pathology and their relationship with default mode network integrity (2011) (6)
- Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals (2021) (6)
- Clinico-Pathological Correlations of the Frontal Lobe Syndrome: Results of a Large Brain Bank Study (2015) (6)
- Medical Clinics of North America. Early diagnosis and intervention in predementia Alzheimer's disease. Preface. (2013) (6)
- Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation (2022) (6)
- Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum (2022) (6)
- Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease (2019) (6)
- Dementia: Mild cognitive impairment—amyloid and beyond (2013) (6)
- Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease (2018) (6)
- Psychosocial Effects of COVID-19 Measures on (Pre-)Dementia Patients During Second Lockdown. (2022) (6)
- Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation (2022) (6)
- A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing (2022) (6)
- Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships (2019) (6)
- Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium-“enhanced” STIR imaging (2004) (6)
- Memantine in moderate-to-severe Alzheimer disease evidence and ethics based? (2004) (6)
- Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum (2019) (6)
- APPLYING RANDOM FOREST MACHINE LEARNING TO DIAGNOSE ALZHEIMER’S DISEASE AND DEMENTIA WITH LEWY BODIES: A COMBINATION OF ELECTROENCEPHALOGRAPHY (EEG), CLINICAL PARAMETERS AND BIOMARKERS (2016) (6)
- Rethinking biobanking and translational medicine in the Netherlands: how the research process stands to matter for patient care (2014) (6)
- Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition (2020) (6)
- Exome sequencing identifies rare damaging variants in the ATP8B4 and ABCA1 genes as novel risk factors for Alzheimer’s Disease (2020) (5)
- TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer’s disease biomarker levels (2020) (5)
- Neurological Signs in Relation to White Matter Hyperintensity Volumes in Memory Clinic Patients (2010) (5)
- Biochemical diagnosis of Alzheimer's disease (2000) (5)
- THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH (2017) (5)
- Familial spastic paraplegia: evidence for a fourth locus (1997) (5)
- Alzheimer's disease: translating neurochemical insights into clinical benefits. (2000) (5)
- LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project (2020) (5)
- Book review: Thompson SBN, Dementia and memory: a handbook for students and professionals. Ashgate. Aldershot, Hampshire, 2006 (2008) (5)
- Erratum to “Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies” [Alzheimer’s & Dementia 2018;14:707-22.] (2019) (5)
- Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies (2021) (5)
- The new criteria for detection and diagnosis of Alzheimer’s disease: From symptoms and signs to neuropsychology, neuroimaging and CSF (2013) (5)
- A novel CCM2 variant in a family with non‐progressive cognitive complaints and cerebral microbleeds (2016) (5)
- Circulating metabolites are associated with brain atrophy and white matter hyperintensities (2020) (5)
- Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study (2020) (5)
- Inflammatory markers in AD and MCI patients with different biomarker profiles—interpretation of serum and CSF levels (2010) (5)
- Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia (2019) (5)
- P2-201 Microglia activation in mild cognitive impairment (2004) (5)
- Idiopathic acute transverse myelitis : Application of the recent diagnostic criteria. Author's reply (2006) (5)
- Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60–102 Years (2019) (5)
- Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old (2021) (5)
- Clinical Applications of Functional Brain MRI (2016) (5)
- MEG CROSS-FREQUENCY ANALYSIS IN PATIENTS WITH ALZHEIMER’S DISEASE (2016) (5)
- Retrograde amnesia for semantic information in Alzheimer's disease (2005) (5)
- Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort (2020) (5)
- WHAT DETERMINES COGNITIVE FUNCTIONING IN THE OLDEST-OLD? THE EMIF-AD 90+ STUDY (2019) (5)
- Does MRI Increase the Diagnostic Confidence of Physicians in an Outpatient Memory Clinic (2016) (5)
- Predicting progression in the late onset frontal lobe syndrome (2018) (5)
- Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease? (2015) (5)
- The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals (2021) (5)
- Routine magnetoencephalography in memory clinic patients: A machine learning approach (2021) (5)
- Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease (2022) (5)
- Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study (2015) (5)
- Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. (2018) (5)
- Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease (2017) (5)
- End Stage Clinical Features and Cause of Death of Behavioral Variant Frontotemporal Dementia and Young-Onset Alzheimer’s Disease (2020) (5)
- Spatial-Temporal Patterns of β-Amyloid Accumulation (2022) (5)
- A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1-42 AND 1-40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS (2018) (4)
- Clustering of autoimmune disease in families at high risk for multiple sclerosis (2007) (4)
- Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias (2021) (4)
- EEG-DIRECTED CONNECTIVITY FROM POSTERIOR BRAIN REGIONS IS DECREASED IN DEMENTIA WITH LEWY BODIES: A COMPARISON WITH ALZHEIMER’S DISEASE AND CONTROLS (2016) (4)
- Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease (2016) (4)
- (99mTc)-HM-PAO SPECT and dementia in Parkinson's disease. (1992) (4)
- Grey zone amyloid burden affects memory function: the SCIENCe project (2020) (4)
- Biomarker testing in MCI patients—deciding who to test (2021) (4)
- Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. (2021) (4)
- Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study (2022) (4)
- CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD (2016) (4)
- Cognitive function and cognitive change in dementia, mild cognitive impairment, and healthy aging: The EDAR study (2010) (4)
- Amyloid‐β CSF/PET discordance vs tau load 5 years later: It takes two to tangle (2020) (4)
- Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease (2022) (4)
- Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 (2021) (4)
- On the path to 2025: understanding the Alzheimer’s disease continuum (2017) (4)
- Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 (2021) (4)
- Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions (2021) (4)
- BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE (2017) (4)
- Souvenaid (R) Improves Memory in Drug-Naive Patients with Mild Alzheimer's Disease: Results from a Randomized, Controlled, Double-Blind Study (Souvenir II) (2012) (4)
- Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface (2022) (4)
- [Cognitive disorders appearing before the age of 65 in patients of the Alzheimer Centre of the VU Medical Centre: diagnoses and clinical characteristics]. (2005) (4)
- Reply from the authors [6] (2007) (4)
- MRI-based biomarkers of preclinical AD (2012) (4)
- Impact of partial volume corrections on quantitative brain PET studies (2012) (4)
- Efficacy, Safety and Biomarker Data from SCarlet RoAD—a Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD (2016) (4)
- Cerebrospinal fluid collection: An informative animation video for patients and caregivers (2019) (4)
- No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease. (1995) (4)
- A double blind, placebo and piracetam controlled, multicenter trial of vinpocetine in dementia of Alzheimer's type and vascular dementia (1992) (4)
- Cognitive Decline in Patients with Chronic Hydrocephalus and Normal Aging: ‘Growing into Deficits’ (2016) (4)
- Biomarkers for Alzheimer’s disease. Which way to go? (2004) (4)
- A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. (2022) (4)
- Anterolateral lumbar meningocele presenting as an ovarian cyst, in a patient with neurofibromatosis (1989) (4)
- A metabolite-based machine learning approach to diagnose Alzheimer’s-type dementia in blood: Results from the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort (2019) (4)
- Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease (2019) (4)
- Alzheimer disease Cerebrospinal Fluid biomarker in Cognitively Normal Subjects : Multicenter 1 Study 2 (2015) (4)
- CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER’S DISEASE: AN ASSAY COMPARISON STUDY (2017) (4)
- Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease (2022) (4)
- Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited (2020) (4)
- Efficacy, Safety and Biomarker Data from SCarlet RoAD - A Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD (S1.002) (2016) (4)
- Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease (2021) (4)
- Genetically identical twins show comparable tau PET load and spatial distribution (2022) (4)
- Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset (2022) (4)
- An Informant Questionnaire for Detecting Alzheimer's Disease: Are Some Items Better Than Others? (2011) (4)
- Functional MRI of the Visual Cortex in Sedated Children with Periventricular Echodensities. (1998) (4)
- Cross-cultural adaptation and validation of the Amsterdam Instrumental Activities of Daily Living questionnaire short version German for Switzerland (2020) (3)
- Epidemiology and risk factors (2005) (3)
- CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION (2014) (3)
- Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline (2023) (3)
- Pathology of cognitively healthy centenarians (2015) (3)
- Evaluating severity of white matter lesions from computed tomography images with convolutional neural network (2020) (3)
- A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging (2022) (3)
- ACTIVE Aβ IMMUNOTHERAPY CAD106 PHASE II DOSE-ADJUVANT FINDING STUDY: SAFETY AND CNS BIOMARKERS (2014) (3)
- White Matter Changes: New Perspectives on Imaging, Clinical Aspects, and Intervention (2011) (3)
- White Matter Changes and Cognitive Decline in a Ten-Year Follow-Up Period: A Pilot Study on a Single-Center Cohort from the Leukoaraiosis and Disability Study (2016) (3)
- The Effect of Alzheimer’s Disease-Associated Genetic Variants on Longevity (2021) (3)
- Trabalho de consenso de força-tarefa da WFSBP sobre marcadores biológicos das demências: contribuição da análise do LCR e do sangue para o diagnóstico precoce e diferencial das demências (2009) (3)
- Can lumbar puncture help to identify patients with incipient Alzheimer's disease? (2006) (3)
- Alzheimer's Disease and Related Disorders (2005) (3)
- Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies (2022) (3)
- Why Is Amyloid-β PET Requested After Performing CSF Biomarkers? (2019) (3)
- Differential trajectories of hypometabolism across cognitively-defined Alzheimer’s disease subgroups (2021) (3)
- Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis (2020) (3)
- Prediction of Alzheimer's Disease in Subjects with Amnestic and Non-amnestic Mci (2013) (3)
- Genetic risk factors for posterior cortical atrophy (2015) (3)
- Nutrition and dementia (2009) (3)
- Functional brain network organization in Alzheimer's disease (2013) (3)
- The efficacy of a medical food (Souvenaid®) in Alzheimer's disease: Results from the first trial and design of future trials (2009) (3)
- High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study (2019) (3)
- GANTENERUMAB TREATMENT REDUCES BIOMARKERS OF NEURONAL AND SYNAPTIC DEGENERATION IN ALZHEIMER’S DISEASE (2016) (3)
- Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial (2018) (3)
- Emerging treatments in dementia. (1997) (3)
- LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY (2017) (3)
- THE PAST, PRESENT, AND FUTURE OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSESSMENTS IN ALZHEIMER'S DISEASE (2016) (3)
- Pre-trained MRI-based Alzheimer's disease classification models to classify memory clinic patients (2020) (3)
- Imaging beta amyloid deposition in vivo: Quantitative comparison of [18F]FDDNP and [11C]PIB (2007) (3)
- High CSF tau predicts rapid decline to Alzheimer's type dementia in MCI subjects with abnormal CSF Aß1-42 (2011) (3)
- Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions (2015) (3)
- Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline (2022) (3)
- Diagnostic impact of [18F]flutemetamol amyloid imaging in young-onset dementia (2015) (3)
- Test–retest variability of [11C]PIB studies in healthy subjects and AD patients (2006) (3)
- Secondary prevention of Alzheimer ' s dementia (2018) (3)
- Small vessel disease lesion type and brain atrophy: The role of co‐occurring amyloid (2020) (3)
- COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI (2017) (3)
- [The development of memory clinics in The Netherlands]. (2007) (3)
- Interneuron hyperexcitability as both causal factor and risk factor in Alzheimer’s disease (2020) (3)
- Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration (2022) (3)
- Comorbid amyloid-β pathology affects clinical and imaging features in VCD (2019) (3)
- Cerebrospinal fluid acetylcholinesterase homospecific activity in patients with “probable Alzheimer's disease” (1994) (3)
- Serum alpha 1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease. (1993) (3)
- [Cholinesterase inhibitors for Alzheimer disease: preliminary recommendations for treatment. Dutch Society for Psychiatry, Section of Geriatric Psychiatry]. (1998) (3)
- Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population (2017) (3)
- Soluble CD 40 Ligand Measurement Inaccuracies Attributable to Specimen Type , Processing Time , and ELISA Method (2005) (3)
- Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology (2020) (3)
- Targeting Lifestyle Behavior to Improve Brain Health: User-Experiences of an Online Program for Individuals with Subjective Cognitive Decline (2020) (3)
- Leuko-Araiosis: Relationship with the type of focal lesions in acute cerebrovascular disorders (1992) (3)
- Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution (2021) (3)
- [Morphological imaging in the diagnosis of dementia. II. Vascular dementia]. (1995) (3)
- Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer’s disease and primary tauopathies (2022) (3)
- RESTING STATE CEREBRAL PERFUSION AND METABOLISM IN SUBJECTIVE MEMORY COMPLAINTS: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA–TWO SIDES OF THE SAME COIN? (2014) (3)
- Effects of reference tissue versus plasma input parametric kinetic modelling on statistical parametric analysis of [11C](R)-PK11195 binding in Alzheimer's disease (AD) and young and old subjects (2005) (3)
- Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline (2018) (3)
- PP172-MON: Effects of a Medical Food on Plasma Micronutrient and Fatty Acid Levels in Mild to Moderate Alzheimer’s Disease (2014) (3)
- CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals (2021) (3)
- Generating diagnostic profiles of cognitive decline and dementia using magnetoencephalography (2021) (2)
- New lexicon and criteria for the diagnosis of Alzheimer's disease – Authors' reply (2011) (2)
- BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project (2021) (2)
- P1-371: New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population (2008) (2)
- Erratum (2021) (2)
- The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease (2020) (2)
- Decreased P-glycoprotein function at the blood–brain barrier in patients with Alzheimer's disease as shown by (R)-[11C]verapamil and PET (2010) (2)
- Chapter 2 Blood pressure and progression of brain atrophy (2013) (2)
- Neuroimaging in old age psychiatry (2004) (2)
- [The behavioural variant of frontotemporal dementia: a challenging diagnosis]. (2013) (2)
- Aggression and multiple sclerosis (1991) (2)
- ALZHEIMER’S DISEASE PATIENTS WITH OSAS HISTORY HAVE HIGHER CSF TAU LEVELS (2016) (2)
- SINGLE-SUBJECT GREY MATTER NETWORKS DETERIORATE 12 YEARS BEFORE DEMENTIA (2019) (2)
- CSF alpha-synuclein is not diagnostic for dementia with Lewy bodies, but related to cognitive decline (2010) (2)
- Diagnostic value of molecular imaging in a memory clinic setting (2012) (2)
- O2.22: The two-year incidence of depression and anxiety disorders in spousal caregivers of persons with dementia: Who is at the greatest risk? (2014) (2)
- Concordance between CSF biomarkers and [11C]PiB-PET in a memory clinic population (2013) (2)
- CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS (2014) (2)
- Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease (2022) (2)
- Provisional research criteria for the behavioral variant of Alzheimer disease: A systematic review and meta-analysis (2021) (2)
- Validation of the Amsterdam IADL questionnaire ®, a new tool to measure instrumental activities of daily living (2011) (2)
- MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER’S DISEASE (2017) (2)
- DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA (2014) (2)
- Comparison of Medial Temporal Lobe Activation in Young and Elderly Subjects and Patients with Alzheimer's Disease. (1998) (2)
- Aβ 34 is a BACE 1-derived degradation intermediate associated with amyloid clearance and Alzheimer ’ s disease progression (2019) (2)
- IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION-SYMPTOM MAPPING STUDY (2018) (2)
- Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial (2022) (2)
- Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD (2021) (2)
- Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals (2022) (2)
- CSF biomarkers in relation to neuroimaging in mild cognitive impairment and Alzheimer's disease (2010) (2)
- Atrophy , hypometabolism and clinical trajectories in amyloid negative probable AD patients (2018) (2)
- Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition (2022) (2)
- Differential Dementia Diagnosis on Incomplete Data with Latent Trees (2016) (2)
- Subjective cognitive decline and self‐reported sleep problems: The SCIENCe project (2022) (2)
- Clusterin: An early biomarker for Alzheimer's disease? (2013) (2)
- Effects of transcutaneous nerve stimulation (TENS) on non-pain related cognitive and beharioural functioning. (2002) (2)
- Contribution of genetic and environmental factors to the onset of preclinical Alzheimer's disease - a monozygotic twin study (2020) (2)
- Diagnostic impact of [18F]flutemetamol PET in early-onset dementia (2017) (2)
- Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report (2021) (2)
- White Matter Lesion Progression in LADIS (2012) (2)
- DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY (2018) (2)
- A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum (2022) (2)
- Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies (2020) (2)
- Classification of Dementia (2002) (2)
- AMYLOID-β LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE (2018) (2)
- DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA (2014) (2)
- Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2018) (2)
- Grey matter networks and clinical progression in subjects with predementia Alzheimer ’ s disease (2017) (2)
- LDL cholesterol and uridine levels in blood are potential nutritional biomarkers of AD progression: The NUDAD project (2020) (2)
- MRI and the Differential Diagnosis of Dementia (2010) (2)
- CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS (2014) (2)
- Lessons Learned in Eastern Europe (2012) (2)
- Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease (2012) (2)
- [Alzheimer's disease and treatment of vascular risk factors]. (2005) (2)
- Getting a grip on Alzheimer's disease: imaging amyloid in the brain (2007) (2)
- Dementia (2009) (2)
- Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline (2021) (2)
- Aspects of Alzheimer's disease Mony J de Leon An atlas of Alzheimer's (2000) (2)
- Corrigendum: White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease (2017) (2)
- Comparison of measurements of medial temporal lobe atrophy in the prediction of Alzheimer's Disease in subjects with MCI (2011) (2)
- Cerebral amyloid burden is associated with white matter hyperintensity location in speci fi c posterior white matter regions Neurobiology of Aging (2019) (2)
- Unbiased detection of atrophy in mild to moderate Alzheimer's disease (2000) (2)
- Detecting functional decline from normal ageing to dementia : development and validation of a short version of the Amsterdam IADL Questionnaire © Alzheimer ’ s & Dementia (2019) (2)
- The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [18F]FDG-PET and pathological assessment (2021) (2)
- Using Magnetic Resonance Imaging in Diagnosing Dementia: A Dutch Outpatient Memory Clinics Survey (2014) (2)
- Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. (2018) (2)
- Heterogeneity in age-related white matter changes Reinhold SchmidtHelena SchmidtJohannes HaybaeckMarisa LoitfelderSerge Weis • Margherita CavalieriStephan SeilerChristian EnzingerStefan RopeleTimo Erkinjuntti • Leonardo PantoniPhilip ScheltensFranz FazekasKurt Jellinger (2011) (2)
- Tau protein spreads through functionally connected neurons in Alzheimer’s disease (2022) (2)
- THE INFLUENCE OF COMORBIDITIES ON COGNITIVE DECLINE AND CONVERSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT (2014) (2)
- P3-023: Comparison of mortality risk between early- and late-onset dementia (2008) (2)
- ePresentation Sessions (2018) (2)
- Cerebral amyloid angiopathy in Alzheimer’s disease is associated with increased blood-brain barrier permeability: A quantitative [11C]PiB-PET study (2013) (2)
- Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer’s disease (2021) (2)
- Neuropsychiatric symptoms of mild cognitive impairment, in Alzheimer’s disease and related disorders annual 2004. (2003) (2)
- Feature extraction and strategy of analyzing structural neuroimaging in dementia. (2008) (2)
- The effect of Alzheimer's disease-associated genetic variants on longevity (2021) (2)
- European consensus for the diagnosis of MCI and mild dementia: Preparatory phase. (2022) (2)
- Simulation and Synthesis in Medical Imaging (2016) (2)
- Neuropathology and cognitive performance in centenarians (2018) (2)
- The 1998 Workshop on Neuroimaging Research in Alzheimer's Disease: Observation and issues (2000) (2)
- Mapping the genetic landscape of early-onset Alzheimer’s disease in a cohort of 36 families (2022) (2)
- Relationship of cerebrospinal fluid biomarkers with in vivo [11C]PIB and [18F]FDDNP binding (2009) (2)
- Clinical use of neuroimaging in dementia: an international perspective (2011) (2)
- EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL β-AMYLOID DEPOSITION IN THE BRAIN (2018) (2)
- Cerebrovascular disease in suspected non‐Alzheimer's pathophysiology and cognitive decline over time (2022) (2)
- All patients with suspected dementia should be scanned at least once with CT or MRI (2006) (2)
- Early onset ApoE-ɛ4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains (2015) (2)
- Longitudinal amyloid imaging using [11]PIB: Choosing the right method (2011) (2)
- Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer’s disease (2022) (2)
- First ever longitudinal [11C]PIB and [18F]FDDNP PET studies in patients with Alzheimer's disease or mild cognitive impairment and healthy controls (2010) (2)
- [Amyloid PET imaging in patients with Alzheimer's disease]. (2017) (2)
- QUALITY ASPECTS OF A NOVEL COGNITIVE-FUNCTIONAL COMPOSITE FOR THE MEASUREMENT OF DISEASE PROGRESSION IN ALZHEIMER’S DISEASE: FEASIBILITY, TEST-RETEST RELIABILITY AND PRACTICE EFFECTS (2017) (2)
- DISEASE-STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER’S DISEASE (2018) (2)
- An Operational Definition of ‘Abnormal Cognition’ to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons? (2020) (2)
- Determining the Minimal Important Change of Everyday Functioning in Dementia (2022) (2)
- P029: A Dutch 24-week randomised controlled study exploring the Effect of a Nutritional Intervention on brain Glucose Metabolism in early Alzheimer's disease (NL-ENIGMA) rationale and design (2014) (1)
- Test-retest repeatability of quantitative [F-18]florbetapir studies in humans (2017) (1)
- Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks (2019) (1)
- Rare variants in IFFO1, DTNB and NLRC3 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation (2021) (1)
- [Contribution of morphological imaging in the diagnosis of dementia. I--Alzheimer disease]. (1994) (1)
- Comparison of digital platforms for participant recruitment in dementia research: Lessons and future directions from a global collaborative (2020) (1)
- EURO‐FINGERS/UK FINGERS (Europe) (2020) (1)
- PERSONALIZED RISK ESTIMATES FOR MCI PATIENTS: TAKING BIOMARKERS INTO THE CLINIC (2016) (1)
- Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. (2020) (1)
- LifeTime and improving European healthcare through cell-based interceptive medicine (2020) (1)
- RESILIENCE TO CLINICAL DEMENTIA AT OLD AGE: THE EUROPEAN MEDICAL INFORMATION FRAMEWORK (EMIF) 90+ STUDY (2016) (1)
- Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis (2020) (1)
- Eigenvector centrality dynamics are related to Alzheimer’s disease pathological changes in non-demented individuals (2023) (1)
- Subject Index Vol. 13, Suppl. 2, 2002 (2002) (1)
- The relationship between cognition and everyday functioning: Let's pay attention! (2012) (1)
- Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer’s disease correlates with pathology (2014) (1)
- Feasibility of an RCT on exercise interventions in early-onset dementia: Let's move on! (2013) (1)
- Using cerebrospinal fluid amyloid‐beta(1‐42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays (2020) (1)
- Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia (2015) (1)
- [DNA diagnostics in dementia]. (2017) (1)
- CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID-β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS (2017) (1)
- DEEP GRAY MATTER ATROPHY DOES NOT PREDICT SHORT-TERM CONVERSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER'S DISEASE (2014) (1)
- IC-P3-229: Assessment of global cortical atrophy and medial temporal lobe atrophy in suspected and definite dementia: Comparison of magnetic resonance imaging and 64 multi-detector row computed tomography (2008) (1)
- CSF proteomic signature predicts progression to Alzheimer's disease dementia (2022) (1)
- DIRECTED ANTERIOR-TO-POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS (2014) (1)
- LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES (2014) (1)
- Small vessel disease lesion type and brain atrophy: The role of coâ•’occurring amyloid (2020) (1)
- Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease (2015) (1)
- P2-331 Differential effects of white matter lesions on medial temporal lobe atrophy in early versus late onset Alzheimer’s disease (2006) (1)
- Disorders Mainly Affecting White Matter (2011) (1)
- MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART (2014) (1)
- EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL β-AMYLOID DEPOSITION IN THE BRAIN (2018) (1)
- RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE (2014) (1)
- Differential Brain Atrophy Patterns and Neurogenetic Profiles in Cognitively-Defined Alzheimer’s Disease Subgroups (2020) (1)
- Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimers disease using a latent class analysis: Neuropsychiatry and behavioral neurology: The neuropsychiatry of subjective cognitive disorder and prodromal AD (2020) (1)
- O1-03-06 Consistency of Resting State Networks across healthy subjects measured with FMRI (2006) (1)
- CSF proteomic profiling of mild cognitive impairment individuals with suspected non‐Alzheimer’s disease pathophysiology (2020) (1)
- EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER’S DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY (2017) (1)
- No evidence for amyloid in the retina of Alzheimer's disease patients (2021) (1)
- Correction to: Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease (2020) (1)
- The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer’s disease (2020) (1)
- Quantitative amyloid PET in the AMYPAD diagnostic and patient management study (2021) (1)
- A loss of neuronal inhibition best explains EEG abnormalities in preclinical Alzheimer’s disease: A multiscale computational modeling study (2020) (1)
- A mixed‐methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living (2020) (1)
- Structural brain imaging (2006) (1)
- [The immune system and Alzheimer's disease]. (2011) (1)
- Plasma proteome profiling identifies changes associated to AD but not to FTD (2022) (1)
- Slowly progressive aphasia without dementia: Differentiation from Alzheimer's disease by means of magnetic resonance imaging (1992) (1)
- Medical nutrition in Alzheimer's disease: First results and clinical trial (2011) (1)
- P2-309 MRI biomarkers as predictors of mortality in dementia (2006) (1)
- Featured Articles Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial (2010) (1)
- Cognitive and CSF biomarkers in older adults, MCI, and dementia (2011) (1)
- IC-P-032 Consistency of resting state networks across healthy subjects measured with fMRI (2006) (1)
- COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER’S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY (2018) (1)
- SUBJECTIVE COGNITIVE DECLINE AND PROGRESSION TO DEMENTIA DUE TO AD AND NON-AD IN MEMORY CLINIC AND COMMUNITY-BASED COHORTS (2016) (1)
- GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY (2018) (1)
- SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER’S DISEASE (2017) (1)
- ADDED VALUE OF MRI BIOMARKERS TO NEUROPSYCHOLOGICAL TEST PERFORMANCE FOR PREDICTION OF AD IN SUBJECTS WITH MCI (2014) (1)
- Grey hair and grey matter (2004) (1)
- Unbiased estimates of CSF beta-amyloid 1-42 cut-points (2013) (1)
- Clinical Features of Patients with Alzheimer's Disease and a History of Traumatic Brain Injury (2022) (1)
- Cultural diversity and the measurement of functional impairment: A cross-cultural validation of the Amsterdam IADL Questionnaire (2019) (1)
- Pathologically proven Alzheimer's disease without medial temporal lobe atrophy: The importance of posterior cerebral atrophy (2011) (1)
- Impaired connectivity between functional brain modules reflects cognitive dysfunction in Alzheimer's disease (2011) (1)
- Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease (2021) (1)
- EXPLORING THE EFFECT OF SOUVENAID ON CEREBRAL GLUCOSE METABOLISM IN EARLY ALZHEIMER’S DISEASE (2019) (1)
- Immune-related genetic enrichment in frontotemporal dementia (2017) (1)
- Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics (2014) (1)
- Mathematical Modeling : Assumptions Affect Results (1)
- THE COGNITIVE-FUNCTIONAL COMPOSITE IS SENSITIVE TO DISEASE PROGRESSION IN MILD COGNITIVE IMPAIRMENT AND EARLY DEMENTIA: LONGITUDINAL FINDINGS FROM THE CATCH-COG STUDY COHORT (2019) (1)
- The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease (2013) (1)
- Cerebral amyloid angiopathy in Alzheimer’s disease is associated with increased blood-brain barrier permeability: A quantitative [11C]PiB-PET study (2013) (1)
- Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative data from the Dutch 100-plus Study (2018) (1)
- IC-P-053 Relevance of temporo-parietal atrophy in MCI conversion to Alzheimer’s disease: A voxel-based morphometry study (2006) (1)
- ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival (2021) (1)
- Dementia prevention in memory clinics: recommendations from the European task force for brain health services (2023) (1)
- Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort (2015) (1)
- DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER’S DISEASE PROGRESSION (2018) (1)
- MEG detects abnormal hippocampal activity in amyloid‐positive MCI (2020) (1)
- VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER’S DISEASE CONTINUUM (2019) (1)
- Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer’s disease (2018) (1)
- Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non‐Alzheimer's disease pathophysiology (2022) (1)
- Subject Index Vol. 17, 2004 (2004) (1)
- Dementia in Parkinson's disease compared with Alzheimer's type dementia. A 99TcHmPAO SPECT study (1992) (1)
- ADDED DIAGNOSTIC VALUE OF CEREBROSPINAL FLUID IN PREDICTING DECLINE IN MEMORY CLINIC SUBJECTS IN CLINICAL PRACTICE (2014) (1)
- Use of biomarkers as endpoint in trials with subjects with preclinical and prodromal Alzheimer's disease: An ADNI study (2012) (1)
- Prediction of amyloid PET status using the LUMIPULSE G β‐amyloid ratio (1‐42/1‐40) (2020) (1)
- Dementia and rapid mortality: Who's at risk? (2015) (1)
- Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study (2022) (1)
- AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER’S DISEASE PATIENTS WITH CURCUMIN (2017) (1)
- Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease (2015) (1)
- Improving diagnosis of dementia in a nationwide setting: First results of the Dutch String of Pearls Initiative on neurodegenerative diseases (2012) (1)
- MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE (2014) (1)
- dopamine and glutamate receptor subtypes as (potential) targets for the pharmacotherapy of Parkinson's disease (1993) (1)
- The predictive value of normal EEGs in dementia due to Alzheimer’s disease (2021) (1)
- Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins? (2015) (1)
- Distinct disease mechanisms may underlie cognitive decline related to hearing loss in different age groups (2023) (1)
- Functional brain networks in AD: Randomization of a “small-world” (2009) (1)
- [Acute subdural hematoma following minor head injury]. (1992) (1)
- No difference in retinal fluorescence after oral curcumin intake in amyloid‐proven AD cases compared to controls (2022) (1)
- MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study (2018) (1)
- The behavioral variant of Alzheimer’s disease does not show a selective loss of Von Economo and phylogenetically related neurons in the anterior cingulate cortex (2022) (1)
- A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future (2020) (1)
- Automatic classification of AD and bvFTD based on cortical atrophy for single-subject diagnosis (2015) (1)
- AMYLOID-BETA DEGRADATION BY HUMAN ASTROCYTES IS IMPAIRED BY APOJ AND APOE (2014) (1)
- ATROPHY SUBTYPES IN ALZHEIMER’S DISEASE IDENTIFIED THROUGH NON-NEGATIVE MATRIX FACTORIZATION (2018) (1)
- VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER’S DISEASE CONTINUUM (2019) (1)
- Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study (2022) (1)
- [Heterogeneity of Alzheimer's disease]. (1993) (1)
- Additional value of CSF Aβ40 levels in the differentiation between FTLD and control subjects (2011) (1)
- An intervention program for caregivers of early-onset dementia patients with frontal behavioral changes: an explorative study increasing their sense of competence (2016) (1)
- Recommendations for the diagnosis and treatment of Alzheimer's disease and other disorders associated with dementia: The EFNS guidelines (2008) (1)
- Medical nutrition in Alzheimer's Disease: Baseline characteristics of 3 Souvenaid® clinical studies (2011) (1)
- Corrigendum to “Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease” [Neuroimage 66 (2013) 28–35] (2013) (1)
- White matter integrity disruption in early amyloid accumulators (2020) (1)
- The behavioral variant of Alzheimer’s disease does not show a selective loss of Von Economo and phylogenetically related neurons in the anterior cingulate cortex (2021) (1)
- STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT (2014) (1)
- Safety, compliance and the effects on memory of 48-week Souvenaid use in mild Alzheimer's disease: Results from the Souvenir II and open-label extension study (2012) (1)
- The impact of COVID‐19 lockdown on cognitive decline over time (2022) (1)
- Social cognition deficits and biometric signatures in the behavioural variant of Alzheimer’s disease (2022) (1)
- Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full? (2013) (1)
- CSF biomarkers predict longitudinal decline in memory and executive functioning in patients with subjective complaints (2013) (1)
- Visual assessment of parametric [11C]PiB images (2012) (1)
- IC-P-102 Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression: The LADIS study (2006) (1)
- Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer’s disease (2015) (1)
- Specificity of available structural markers on MRI (2009) (1)
- Structural and functional brain imaging and dementia diagnosis (2000) (1)
- Protocols for cognitive enhancement. A user manual for Brain Health Services—part 5 of 6 (2021) (1)
- The Souvenaid® clinical trial program for Alzheimer's disease (2011) (1)
- Structural neuroimaging: CT and MRI (2009) (1)
- Blood pressure and progression of brain atrophy—lower is not always better: The SMART-MR study (2012) (1)
- Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease (2015) (1)
- Longitudinal change in ATN biomarkers in cognitively normal individuals (2022) (1)
- P2-222 A comparison of whole-brain activation during face encoding between healthy aging, mild cognitive impairment and Alzheimer's disease (2004) (1)
- Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full? (2013) (1)
- Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD (2020) (1)
- Diagnostic impact of [18F]flutemetamol amyloid imaging in young onset dementia (2015) (1)
- CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID-β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS (2017) (1)
- Featured Article Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease (2015) (1)
- The ATN Framework-Moving Preclinical Alzheimer Disease to Clinical Relevance. (2022) (1)
- Age-related differences in functional connectivity of resting-state EEGs in Alzheimer's disease (2012) (1)
- THINNER CORTICAL THICKNESS IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE IS RELATED TO POOR MEMORY PERFORMANCE AND FASTER DECLINE OF EXECUTIVE FUNCTION (2016) (1)
- Design of a patient‐ and investigator‐blind, randomized, placebo‐controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003 (2021) (1)
- SPECT, CT and MRI in a Turkish family with huntington's disease (1993) (1)
- Satellite Symposia (2009) (1)
- Heterogeneity of Alzheimer’s disease: consequence for drug trials? (2018) (1)
- Magnetic Resonance and Dementia (2002) (1)
- Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. (2019) (1)
- The relation between eeg spectral analysis and clinical progression in non-demented, amyloid-positive subjects (2015) (1)
- P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles (2022) (1)
- Longitudinal changes in specific [11C]PIB and [18F]FDDNP binding: Paired PET studies in patients with Alzheimer's disease, mild cognitive impairment and healthy controls (2011) (1)
- Cerebrospinal fluid biomarkers for Alzheimer's disease and specific cognitive decline in subjects with mild cognitive impairment (2012) (1)
- Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly (2015) (1)
- Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia (2012) (1)
- An overview of the medical food Souvenaid clinical trial program (2013) (1)
- Recomendações para o diagnóstico e tratamento da doença de Alzheimer e de outras doenças associadas a demência: Orientações da EFNS (2008) (1)
- Multi-site hippocampal subfields reproducibility: A european 3T study (2015) (1)
- Cerebrospinal fluid markers for predicting Alzheimer's-type dementia in subjects with amnestic versus non-amnestic mild cognitive impairment (2012) (1)
- Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment. (2022) (1)
- [The value of new diagnostic techniques in Alzheimer's disease]. (1992) (1)
- Prognosis of Alzheimer’s disease; what do patients and care partners want to know? (2020) (1)
- Influence of incidental off-resonance RF excitation in conventional multislice T1-weichted SE MR imaging: Implications for assessment of “Black holes” (1995) (1)
- Reply from the authors [2] (2007) (1)
- TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2017) (1)
- Biochemical markers for Alzheimer's disease in cerebrospinal fluid (2009) (1)
- Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6 (2021) (1)
- Giving meaning to the scores of the Amsterdam instrumental activities of daily living questionnaire: a qualitative study (2022) (1)
- EEG DIRECTED CONNECTIVITY FROM POSTERIOR BRAIN REGIONS IS DECREASED IN DEMENTIA WITH LEWY BODIES: A COMPARISON WITH ALZHEIMER’S DISEASE AND CONTROLS (2016) (1)
- MATTERS ARISING (1991) (1)
- 19th biennial IPEG Meeting (2016) (1)
- Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6 (2021) (1)
- DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD (2018) (1)
- Increased parietal amyloid burden and metabolic dysfunction in Alzheimer's disease (2012) (1)
- Correction to: Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer’s disease and primary tauopathies (2022) (1)
- DEVELOPMENT AND USABILITY OF ADAPPT: AN ONLINE TOOL TO SUPPORT CLINICIANS, PATIENTS AND CAREGIVERS IN THE DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE (2019) (1)
- CSF and MRI biomarkers as predictors for Alzheimer's-type dementia in subjects with mild cognitive impairment (2011) (1)
- FMRI of the visual cortex: A pilot study in patients with optic neuritis using monocular stimulation (1997) (1)
- Patterns of cerebral atrophy detected by voxel-based morphometry (VBM) in Alzheimer's disease (2002) (1)
- Subject Index Vol. 13, Suppl. 2, 2002 (2002) (1)
- DATA-DRIVEN TAU-PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER’S DISEASE (2017) (1)
- Data-driven detection of latent atrophy factors related to phenotypical variants of posterior cortical atrophy (2019) (1)
- Alzheimer’s biomarkers in daily practice (ABIDE): Study design (2015) (0)
- Subject Index Vol. 20, 2005 (2005) (0)
- Contents Vol. 26, 2008 (2008) (0)
- IDENTIFICATION OF PHENOTYPIC CLUSTERS OF AD PATIENTS AND CONTROLS USING CLASSIFICATION AND REGRESSION TREE MODELS (2014) (0)
- Late Breaking News (2003) (0)
- P2-227 A comparison of medial temporal lobe atrophy ratings with linear and volumetric measures in aging and dementia (2004) (0)
- From corticocentrism to leucocentrism or both. (2017) (0)
- Progress in CSF biomarker discovery for mild cognitive impairment and Alzheimer's Disease by label-free quantitative proteomics (2011) (0)
- Neuronal network hyperactivity in computational models of AD (2020) (0)
- In vivo tau pathology is associated with synaptic loss and altered synaptic function (2021) (0)
- Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning (2015) (0)
- 4 . 2 MRI characteristics of clinical subtypes of mild cognitive impairment (2012) (0)
- Changes in Brain-Health Related Modifiable Risk Factors in Older Adults After One Year of COVID-19-Restrictions (2022) (0)
- Corpus callosum atrophy in Alzheimer's disease and subcortical vascular dementia: The LADIS study (2010) (0)
- ATROPHY PATTERNS PREDICTING COGNITIVE DECLINE IN NON-DEMENTED SUBJECTS ARE INDEPENDENT OF AMYLOID PATHOLOGY (2016) (0)
- Potential of PET to predict cognitive decline along the continuum of Alzheimer's disease (2011) (0)
- THE COMBINATION OF HIPPOCAMPAL ATROPHY ON MRI AND CSF IS A BIOMARKER FOR FRONTOTEMPORAL DEMENTIA IN EARLY ONSET DEMENTIA (2014) (0)
- Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment (2015) (0)
- IC-03-05 EEG DIRECTED CONNECTIVITY FROM POSTERIOR BRAIN REGIONS IS DECREASED IN DEMENTIAWITH LEWY BODIES: A COMPARISON WITH ALZHEIMER’S DISEASE AND CONTROLS (2019) (0)
- The Value of QEEG Prefrontal Theta Cordance in the Prediction of Response to Various Antidepressants (2019) (0)
- IC-02-04: White matter hyperintensities in Alzheimer patients and non-demented elderly: Postmortem quantitative MRI and neuropathological characteristics (2008) (0)
- Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum (2020) (0)
- P1-413 CARLINA ACAULIS HAS ANTIOXIDANT EFFECTS AND AMELIORATES BETA-AMYLOID TOXICITY IN A C. ELEGANS MODEL (2014) (0)
- THE DUTCH DEMENTIA DELTA PLAN (DDDP) (2016) (0)
- A-oligomers Quantification in Csf, and Their Clinical Value 4.2 Amyloid-oligomers Relate to Cognitive Decline in Alzheimer's Disease (2014) (0)
- Neuropathology and cognitive performance in self-reported cognitively healthy centenarians (2018) (0)
- Cerebral blood flow measured with arterial spin–labeled perfusion MRI at 3T and structural brain changes in Alzheimer's disease (2012) (0)
- Machine learning to arterial spin labeling in Mild cognitive impairment and alzheimer Disease 1 (0)
- Data‐driven evidence for three distinct patterns of amyloid‐β accumulation (2021) (0)
- P3-043 Inflammatory markers CRP and IL-6 in cerebrospinal fluid and serum in relation to the IL-6 genotype in patients with Alzheimer's disease (2004) (0)
- Slow gait speed and weak grip strength are related to worse attention and psychomotor speed in preclinical stages of dementia (2015) (0)
- Alzheimer's disease patients with microbleeds and additional white matter hyperintensities: Does it matter? (2012) (0)
- P2-132 Inflammatory markers in MCI and AD patients with different biomarker profiles (2006) (0)
- IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATE-ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY (2018) (0)
- A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER’S DISEASE (2019) (0)
- Graph theoretical analysis of resting-state EEG in mild cognitive impairment: A longitudinal study (2010) (0)
- Exploring the biomarker cascade model: Relating cortical volume loss to [11C]PiB, [18F]FDG and MMSE over time in Alzheimer's disease patients and normal controls (2012) (0)
- A COMPARISON OF EEG CONNECTIVITY OUTCOME MEASURES FOR ALZHEIMER’S DISEASE IN A DOUBLE-BLINDED RANDOMIZED CLINICAL TRIAL OF PQ912 (2018) (0)
- Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease (2015) (0)
- Physical activity, independent functioning and emotional well-being in early-onset dementia (2013) (0)
- MULTIMODAL BRAIN NETWORK ALTERATIONS IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT PATIENTS (2014) (0)
- P1-181 CSF Abeta38, Abeta40 and Abeta42 levels in Alzheimer's disease patients and controls (2004) (0)
- Hippocampal atrophy on MRI in the diagnosis of Alzheimer's disease (2002) (0)
- The usefulness of the IQCODE in a memory clinic setting (2009) (0)
- Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline (2020) (0)
- Do microbleeds predict stroke in Alzheimer's disease (MISTRAL)? Study design and first results (2013) (0)
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease (2017) (0)
- P3-079: CSF biomarker levels, APOE genotype and the effect of aging (2008) (0)
- Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI (2020) (0)
- PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY (2018) (0)
- More white matter hyperintensities and smaller brain volumes are related to lower cerebral blood flow measured with 3T arterial spin labeling magnetic resonance imaging (2013) (0)
- COMORBID AMYLOID-β PATHOLOGY AFFECTS NEUROPSYCHIATRIC, NEUROPSYCHOLOGICAL, AND IMAGING FEATURES IN VASCULAR COGNITIVE DISORDERS (2019) (0)
- Chapter 8 BRI 2 correlates with markers reflecting Alzheimer ’ s disease pathology in human cerebrospinal fluid (2015) (0)
- Concordance between CSF biomarkers and [11C]PIB PET in a memory clinic population (2013) (0)
- Impact of the disclosure of amyloid‐PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS) (2020) (0)
- FREE PAPERS: ORAL SESSIONS ORAL SESSION 1: ALZHEIMERS DISEASE 73636: Distinct Patterns of BOLD Activation Using Functional Magnetic Resonance Imaging (fMRI) in Individuals at Genetic Risk for Developing AD Compared to Healthy Controls (2011) (0)
- PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER’S PATIENTS AND CONTROLS USING FLORTAUCIPIR (2017) (0)
- The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease (2014) (0)
- Left-handedness, learning disability, autoimmune disease, and seizure history influence age at onset and phenotypical targeting of Alzheimer's disease (2022) (0)
- Grey matter graph properties are related to disease severity in Alzheimer's disease (2013) (0)
- [18F]FLORTAUCIPIR BINDING STRONGLY CORRELATES TO COGNITION ACROSS THE CLINICAL ALZHEIMER’S DISEASE CONTINUUM, INDEPENDENTLY OF CSF TAU (2019) (0)
- DIFFERENTIAL EXPRESSION OF POLYGENIC RISK IN CEREBROSPINAL FLUID PROTEOMIC MEASURES IN ALZHEIMER’S DISEASE (2019) (0)
- Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease (2018) (0)
- IS SORL1 AN AUTOSOMAL DOMINANT ALZHEIMER GENE? (2018) (0)
- P2-365 ADDED DIAGNOSTIC VALUE OF 18F- FLUTEMETAMOL PET SCANNING IN YOUNG PATIENTS WITH DEMENTIA QUANTIFYING MITOCHONDRIAL AND SYNAPTIC FUNCTION IN ALZHEIMER’S DISEASE USING 18 F]BCPP-EF, [ 11 AND [ 11 C]UCB-J PET IMAGING (2019) (0)
- GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER’S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE (2019) (0)
- NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia (2005) (0)
- Alzheimer’s disease core biomarkers and prediction of dementia in MCI: The effect of age at onset (2015) (0)
- Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [18F]flortaucipir PET study (2021) (0)
- Translating network activity in an Alzheimer mouse model to human Alzheimer's disease mutation carriers (2022) (0)
- GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE (2017) (0)
- Medical nutrition in disease management of Alzheimer's patients (2013) (0)
- AMYPAD-DPMS PRELIMINARY RESULTS: PARTICIPANTS’ BASELINE FEATURES (2019) (0)
- IMPACT OF CO-MORBID AMYLOID PATHOLOGY ON CLINICAL PHENOTYPE OF PATIENTS WITH VASCULAR COGNITIVE DISORDERS (2016) (0)
- ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [18F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS (2018) (0)
- THE 100-PLUS STUDY: WHAT THE OLDEST-OLD CAN TEACH US (2014) (0)
- The use of amyloid‐PET in memory clinic patients: AMYPAD Diagnostic and Patient Management Study (2022) (0)
- CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2017) (0)
- The association between caregiver burden and diagnosis in a memory clinic setting is modified by gender (2012) (0)
- IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOGY OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIF-AD 90+ STUDY (2018) (0)
- Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to AD among subjects with mild cognitive impairment (2016) (0)
- CSF, MRI, and APOE biomarkers as predictors for Alzheimer-type dementia in subjects with amnestic versus non-amnestic mild cognitive impairment (2011) (0)
- Featured Article Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease (2016) (0)
- P2-200 Patterns of brain atrophy in early-onset versus late-onset Alzheimer's disease: relevance of posterior cingulate atrophy (2004) (0)
- Temporal evolution of biomarkers and cognitive markers from preclinical to clinical Alzheimer's disease: An Alzheimer's Disease Neuroimaging Initiative (ADNI) study (2013) (0)
- Biomarker Based and Individualized Prognosis for Patients with Mild Cognitive Impairment: Towards a Personalized Medicine Approach for AD (2019) (0)
- A New Concept and New Criteria for Alzheimer's Disease (2007) (0)
- An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project (2021) (0)
- Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort (2019) (0)
- Differential diagnosis of dementia combining web‐based cognitive testing and MRI (2020) (0)
- Alzheimer's disease and related disorders annual 5 / (2014) (0)
- White matter lesions on MRI in older individuals: Alzheimer's disease? (1991) (0)
- Progression in late onset frontal lobe syndrome (2016) (0)
- Evaluation of compartment models and semi-quantitative measures for analysing [18F]FDDNP studies (2007) (0)
- Quantitative regional validation of the rating scale for posterior cortical atrophy (2013) (0)
- CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS (2014) (0)
- A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging (2022) (0)
- PLASMA AMYLOID AS A PRE-SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE (2018) (0)
- 596 Predictive value of medial temporal lobe volume for cognitive decline in normal community dwelling elderly (1996) (0)
- CONCORDANCE OF [18F]FLUTEMETAMOL AMYLOID DEPOSITION IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2016) (0)
- WHEN LESS IS MORE: DETECTING FUNCTIONAL DECLINE USING A SHORT VERSION OF THE AMSTERDAM IADL QUESTIONNAIRE (2016) (0)
- S0033291718000594jra 132..139 (2018) (0)
- DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION (2017) (0)
- Are Biomarkers Valid as Surrogates for Treatment Effects in Alzheimer’s Disease? (2009) (0)
- PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER’S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES (2017) (0)
- QUANTIFICATION OF TAU LOAD USING [18F]AV-1451 AND PET (2016) (0)
- Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling (2021) (0)
- Serum neurofilament light in memory clinic practice (2020) (0)
- Associations of nutritional parameters with clinical progression in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer’s disease: The NUDAD project (2020) (0)
- OPTIMIZING COGNITIVE OUTCOMES FOR BIOMARKER POSITIVE INDIVIDUALS AT DIFFERENT CLINICAL STAGES OF ALZHEIMER’S DISEASE ACCORDING TO THE NIA-AA RESEARCH FRAMEWORK (2019) (0)
- The EMIF-AD PreclinAD study: study design and baseline cohort overview (2018) (0)
- DECREASED CSF AMYLOID BETA 38, 40 AND 42 IN GENETICALLY AND PATHOLOGICALLY CONFIRMED FTD (2019) (0)
- NON-AMNESTIC ALZHEIMER’S DISEASE: A POSSIBLE ROLE FOR NEUROINFLAMMATION? (2017) (0)
- The plasma peptidome (2018) (0)
- Heterogeneous distribution of pathology in behavioral variant Alzheimer’s disease (2020) (0)
- Test retest analysis of fMRI using visual stimulation: EPI compared to FLASH (1997) (0)
- Assessment of cortical vulnerability of the anterior cingulate cortex in the behavioral variant of Alzheimer’s disease (2020) (0)
- Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review (2021) (0)
- GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS (2016) (0)
- THE REST-ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLY-ONSET DEMENTIA (2014) (0)
- BIOMARKERS FOR VASCULAR CONTRIBUTIONS TO DEMENTIA (2016) (0)
- ERRATUM. (2021) (0)
- Medical Nutrition in Alzheimer's Disease: The Souvenaid® Clinical Trial Program (2010) (0)
- [Medical nutrition in Alzheimer's: the trials]. (2013) (0)
- TRAJECTORIES OF COGNITIVE DECLINE IN VARIOUS TYPES OF DEMENTIA (2014) (0)
- Genetic contribution to grey matter network disruptions and Alzheimer disease cerebrospinal fluid markers (2022) (0)
- Rationale and design of the “NEurodegeneration: Traumatic brain injury as Origin of the Neuropathology (NEwTON)” study: a prospective cohort study of individuals at risk for chronic traumatic encephalopathy (2022) (0)
- Exploring the biomarker cascade model: Relating cortical volume loss to [11C]PIB, [18F]FDG and MMSE over time in Alzheimer's disease patients and normal controls (2012) (0)
- Overview of current treatments: pros and cons & new amyloid lowering strategies: do they work clinically ? (2008) (0)
- EEG slowing in predementia Alzheimer's disease is compatible with neuronal hyperactivity: A multiscale computational modeling study (2021) (0)
- Atrophy subtypes in Alzheimer ’ s disease are detectable in prodromal stage and associated with different cognitive trajectories (2019) (0)
- More white matter hyperintensities and smaller brain volumes are related to lower cerebral blood flow as measured with 3T arterial spin labeling MRI (2013) (0)
- Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas (2018) (0)
- High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study (2019) (0)
- P3-099: Serum Amyloid P component as biomarker in Alzheimer's disease (2008) (0)
- ID 66 – Effect of a medical food on macroscopic brain activity in mild Alzheimer’s disease: Results from an exploratory double blind, randomised controlled magnetoencephalography study (2016) (0)
- Post‐mortem assessment of retinal phosphorylated tau and amyloid beta in a cohort of neurodegenerative diseases. (2022) (0)
- THE DIAGNOSTIC VALUE OF AMYLOID PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS (2016) (0)
- Longitudinal change in ATN biomarkers in cognitively normal individuals (2022) (0)
- A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients (2015) (0)
- Subject Index Vol. 29, 2010 (2010) (0)
- Association between GWAS SNPs and CSF, MRI and cognition among subjects with MCI: Findings from the DESCRIPA study (2012) (0)
- NEUROIMAGING: BRAIN CONNECTIVITY O3-08-01 GREY MATTER CONNECTIVITY IS ASSOCIATED WITH TIME TO CLINICAL PROGRESSION IN MILD COGNITIVE IMPAIRMENT, INDEPENDENT OFAMYLOID STATUS (2019) (0)
- Preclinical and Clinical Studies of p38α MAP kinase inhibition to Treat Basal Forebrain Cholinergic Dysfunction and Degeneration (2021) (0)
- Leuko-Araiosis: Relationship with the types of focal lesions in cerebrovascular disorders (1992) (0)
- Predictive accuracy for Alzheimer's Disease of CSF Aß1-42, hippocampal atrophy and APOE genotype in MCI subjects depends on age (2011) (0)
- WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE (2018) (0)
- Functional eigenvector centrality dynamics are related to amyloid deposition in preclinical Alzheimer’s Disease (2022) (0)
- BINDING PROPERTIES OF CURCUMIN IN POSTMORTEM BRAIN TISSUE: TOWARD AMYLOID IMAGING IN THE RETINA? (2018) (0)
- Subjective cognitive decline (2021) (0)
- COGNITIVE PERFORMANCE AND ALZHEIMER-ASSOCIATED PATHOLOGY IN THE CONTEXT OF EXTREME AGING (2017) (0)
- P1-307: Assessment of global cortical atrophy and medial temporal lobe atrophy in suspected and definite dementia: Comparison of magnetic resonance imaging and 64 multidetector row computed tomography (2008) (0)
- PT02.1: Poorer Memory is Related to Poorer Odor Discrimination and Identification in Mild Cognitive Impairment and Alzheimer’s Disease: The Nudad Project (2019) (0)
- FingerprintingAlzheimer’s Diseaseby 1H Nuclear Magnetic ResonanceSpectroscopy of Cerebrospinal Fluid (2020) (0)
- IC-03-01: Imaging Alzheimer pathology in vivo: Quantitative comparison of [11C]PIB and [18F]FDDNP (2008) (0)
- P1-300: Imaging Alzheimer pathology in vivo: Quantitative comparison of [11C]PIB and [18F]FDDNP (2008) (0)
- Nutritional status and structural brain changes in Alzheimer’s disease: TheNUDADproject (2020) (0)
- Safety , tolerability and efficacy of the glutaminyl cyclase inhibitor PQ 912 in Alzheimer ' s disease : results of a randomized , double-blind , placebo-controlled phase 2 a stud (0)
- THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER’S DISEASE (2018) (0)
- Depressive symptoms predict cognitive impairment in nondisabled elderly with white matter changes: The LADIS study (2009) (0)
- A NOVEL NEUROIMAGING APPROACH TO CAPTURE COGNITIVE RESERVE (2016) (0)
- A stepwise approach towards diagnostic workup in dementia using online cognitive tools (2021) (0)
- REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELY-DEFINED SUBGROUPS OF ALZHEIMER’S DISEASE (2019) (0)
- PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases (2019) (0)
- AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PRE-AD COHORT (2018) (0)
- The probabilistic model of Alzheimer disease: the amyloid hypothesis revised (2021) (0)
- Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future (2013) (0)
- II.P19 The use of electroencephalograhy in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies (2006) (0)
- [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE (2017) (0)
- AN RCT TO IDENTIFY BEST PRACTICES FOR DISCLOSURE OF AMYLOID IMAGING RESULTS IN MILD COGNITIVE IMPAIRMENT: THE ABIDE SIMULATION-STUDY (2019) (0)
- ORIGINAL RESEARCH Open Access Reproducibility of quantitative (R)-( 11 C)verapamil (2012) (0)
- Predictive accuracy of the extended Predementia Alzheimer disease Scale (PAS) for Alzheimer-type dementia in subjects with MCI (2005) (0)
- COMPARING THE COGNITIVE-FUNCTIONAL COMPOSITE WITH TRADITIONAL TESTS OF COGNITION AND FUNCTION: FINDINGS FROM THE CATCH-COG STUDY COHORT (2018) (0)
- DIETARY INTAKE AND NUTRIENT LEVELS OF B-VITAMINS AND OMEGA-3 FATTY ACIDS ARE DIFFERENTIALLY ASSOCIATED IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE: THE NUDAD PROJECT (2019) (0)
- White matter hyperintensities compromise executive functioning networks in mild cognitive impairment: the longitudinal DESCRIPA study. (2010) (0)
- COGNITIVE SUBTYPES IDENTIFIED USING NONNEGATIVE MATRIX FACTORISATION IN FOUR LARGE ALZHEIMER'S DISEASE DEMENTIA COHORTS (2016) (0)
- CONTACTIN-2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT (2018) (0)
- Validation and Comparison of NIA-AA and IWG Diagnostic Criteria for Alzheimer's Disease in MCI Patients Coming from Three European Memory Clinics (IN3-2.005) (2013) (0)
- Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2017) (0)
- Alzheimer's disease: a broad overview Howard H Feldman Atlas of Alzhei (2008) (0)
- Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI (2022) (0)
- Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey (2019) (0)
- Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study (2019) (0)
- THE INFLUENCE OF CONCOMITANT ALZHEIMER PATHOLOGY ON ATROPHY IN DEMENTIA WITH LEWY BODIES (DLB): A COMPARATIVE MRI STUDY (2016) (0)
- Five pathophysiological Alzheimer’s disease subtypes detected with unsupervised clustering of CSF proteomics (2022) (0)
- Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia (2018) (0)
- ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [18F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS (2018) (0)
- Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment (2017) (0)
- P2-281 Fluid registration derived hippocampal atrophy rates: Reliability and comparison with manual measures, a methodological approach (2006) (0)
- SUN-PO264: Resting Energy Expenditure of Patients with Alzheimer’s Disease, Mild Cognitive Impairment and Controls: The Nudad Project (2019) (0)
- Neuropsychiatric symptoms in patients with possible vascular cognitive impairment, does sex matter? (2021) (0)
- P1-149 CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER’S DISEASE THE (2014) (0)
- VASCULAR DEMENTIA AND DIETARY PATTERN: A SUBPOPULATION ANALYSIS OF THE ADVENTIST HEALTH STUDY-2 (2018) (0)
- Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCe project (2020) (0)
- PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER’S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE (2017) (0)
- Heterogeneity of atrophy patterns in mild cognitive impairment and relationship to CSF biomarkers of Alzheimer's pathology (2011) (0)
- Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning (2022) (0)
- NEUROLOGY): NEUROPSYCHIATRIC SYMPTOMS ACROSS THE SPECTRUM OFAD O2-11-01 CROSS-SECTIONAL ASSOCIATIONS BETWEEN CSF BIOMARKERS OF AMYLOID AND TAU WITH NEUROPSYCHIATRIC SYMPTOMS: THE MAYO CLINIC STUDY OFAGING (2019) (0)
- PP038-SUN MEDICAL NUTRITION IN DISEASE MANAGEMENT OF ALZHEIMER'S PATIENTS (2013) (0)
- METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAM-VCI STUDY (2018) (0)
- Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies (2021) (0)
- EPIDEMIOLOGY AND RISK FACTORS OF DEMENTIA W M van der Flier , P Scheltens (2005) (0)
- Contents Vol. 24, 2007 (2007) (0)
- [Detection of dementia of the Alzheimer type with the 7 Minutes Test (7 MT)]. (2004) (0)
- Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology (2015) (0)
- MRI in patients with probable Alzheimer's disease, compared with MR findings in patients suffering from diabetes, vascular disease, and normal controls Scientific meeting of the Netherlands Society of Neurology, held in Amsterdam, 22nd of April 1989 (1989) (0)
- Comparison of 4 putative MR imaging marker of matrixdestruction in MS plaques (1995) (0)
- Use of image derived input functions for [11C]PIB studies : Assessment of accuracy and test-retest variability (2007) (0)
- 5th Conference Clinical Trials on Alzheimer’s Disease (2012) (0)
- The medical food Souvenaid improves memory performance and preserves functional connectivity in mild Alzheimer'/INS;s disease (AD) (2013) (0)
- Contents Vol. 30, 2008 (2008) (0)
- Neurology in Practice and Practical (2006) (0)
- PROGNOSIS OF INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT REVERTING TO NORMAL COGNITION (2018) (0)
- Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results (2021) (0)
- Multisite hippocampal subfields reproducibility: A european 3T study (2015) (0)
- P36.4 Differences in EEG synchronisation likelihood measurements between young and old onset Alzheimer’s disease (2006) (0)
- P1-235: An automated method for measuring longitudinal volume changes of the ventricular system (2008) (0)
- Advanced insight in treatment options. (2008) (0)
- Quantification of [18 F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE project. (2022) (0)
- DNA-diagnostiek bij dementie (2017) (0)
- [Drugs for Alzheimer disease: what will the minister decide]. (1998) (0)
- Neuro-imaging in dementia: using MRI in routine work-up (2007) (0)
- MRI and CT in the diagnosis of vascular dementia. J Neurol Sci (2004) (0)
- Subject Index Vol. 30, 2008 (2008) (0)
- PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDE-BASED MICROARRAY PLATFORM (2014) (0)
- POOLED AMYLOID PET BASELINE DATA FROM THE BAPINEUZUMAB IV PHASE III TRIALS (2016) (0)
- Discrimination of Alzheimer's disease from cognitively healthy individuals: an arterial spin labeling MRI study (2010) (0)
- Rare missense variant (R251G) on APOE counterbalances the Alzheimer’s disease risk associated with APOE‐ε4 (2022) (0)
- 12. A correlative triad of clinical, gadolinium-DTPA-enhanced MRI and CSF myelin basic protein in multiple sclerosis patients treated with high dose intravenous methylprednisolone (1992) (0)
- Drug development in Alzheimer’s disease: the path to 2025 (2016) (0)
- 6. Atrophy of the medial temporal lobes as early marker in Alzheimer's disease: a MRI study (1992) (0)
- Eleventh meeting of The European Neurological Society21–25 April, 2001, Paris, France (2001) (0)
- Genetic contribution to grey matter network disruptions and Alzheimer disease cerebrospinal fluid markers (2022) (0)
- Performance evaluation of various reference tissue input parametric methods: For [18F]FDDNP (2007) (0)
- Intrathecal chemochine levels in cortical lobar degenerations (2005) (0)
- Mapping the genetic landscape of early-onset Alzheimer’s disease in a cohort of 36 families (2022) (0)
- Genome-wide association study of Alzheimer's disease brain imaging biomarkers and neuropsychological phenotypes in the EMIF-AD Multimodal Biomarker Discovery dataset (2021) (0)
- UNBIASED METHOD TO DETERMINE CUT-POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER’S DISEASE POPULATION (2018) (0)
- Abstracts of the Symposia (2006) (0)
- Biomarkers in dementia : The Dutch Parelsnoer Initiative on neurodegenerative diseases (2011) (0)
- THE DIAGNOSTIC VALUE OF AMYLOID PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS (2016) (0)
- O1-03-04 Relevance of temporo-parietal atrophy in MCI conversion to Alzheimer’s disease: A voxel-based morphometry study (2006) (0)
- FDG-PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELY DEFINED SUBGROUPS OF ALZHEIMER’S DISEASE (2019) (0)
- MISMATCH BETWEEN CLINICAL AND NEUROPATHOLOGICAL DIAGNOSIS OF DEMENTIA: HOW CAN BIOMARKERS HELP? (2017) (0)
- LARGE-VESSEL DISEASE AND [18F]FLUTEMETAMOL-AMYLOID DEPOSITION IN COGNITIVELY HEALTHY ELDERLY TWINS (2016) (0)
- USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NON-ALZHEIMER’S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT (2017) (0)
- IC-P2-100: Diagnostic utility of cross-sectional and longitudinal hippocampal volumetry in memory clinic patients (2008) (0)
- [Chronic traumatic encephalopathy: an old acquaintance in athletes]. (2017) (0)
- Protein kinase activity profiling and identification of signalling pathways involved in Alzheimer's disease (2010) (0)
- THE ASSOCIATION BETWEEN [18F]AV1451 PET AND COGNITIVE PERFORMANCE ACROSS THE ALZHEIMER’S DISEASE SPECTRUM (2018) (0)
- DIFFERENT CORTICAL NEURONAL VULNERABILITY IN DEMENTIA WITH AND WITHOUT PREDOMINANT BEHAVIOURAL SYMPTOMS (2018) (0)
- BRI2 DEMENTIA PATHWAY IN CSF, IMPROVING DETECTION THROUGH ULTRASENSITIVE SIMOA TECHNOLOGY (2017) (0)
- A NOVEL NEUROIMAGING APPROACH TO CAPTURE COGNITIVE RESERVE (2016) (0)
- Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals (2020) (0)
- Podium Presentations: Thursday, July 23, 2015 P326 O5-05-03 NEUROGRANIN, A CSF BIOMARKER FOR SYNAPTIC LOSS, PREDICTS DECLINE TO DEMENTIA DUE TO ALZHEIMER’S DISEASE (2015) (0)
- The role of the parahippocampal cortex in spatial memory: an fMRI Study (2001) (0)
- Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool (2015) (0)
- Overlap of Neuroanatomical Involvement in Frontotemporal Dementia and Primary Psychiatric Disorders: A Meta-analysis (2022) (0)
- Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years (2023) (0)
- Cerebral atrophy in dementia with Lewy bodies studied using voxel-based morphometry (2002) (0)
- Effects of MR based attenuation correction on clinical interpretation and quantification of [18F]flutemetamol scans: A comparison between PET/CT and PET/MR (2015) (0)
- ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT-LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS (2019) (0)
- AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS (2018) (0)
- How to Use This Book (2011) (0)
- Performance evaluation of various parametric methods : For [11C]PIB (2007) (0)
- Early‐onset Alzheimer’s disease is related to differential spatial patterns of tau pathology and cognitive impairment (2020) (0)
- GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT (2017) (0)
- DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA (2018) (0)
- Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology (2015) (0)
- Measuring instrumental activities of daily living (IADL) in dementia: Review of scales (2017) (0)
- Cerebrospinal fluid biomarkers of frontotemporal lobar degeneration (2016) (0)
- TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2017) (0)
- Associations between gut microbiota composition and AD biomarkers (2021) (0)
- CHAPTER 5 Amyloid-independent atrophy patterns predict time to progression to dementia in MCI (2017) (0)
- P2-070: Increased randomness of functional brain networks in Alzheimer's disease: ‘small-world' network analysis of non-linear functional connectivity (2008) (0)
- Parametric event-related fMRI of word encoding and retrieval (2001) (0)
- [18F]FLORTAUCIPIR BINDING STRONGLY CORRELATES TO COGNITION ACROSS THE CLINICAL ALZHEIMER’S DISEASE CONTINUUM, INDEPENDENTLY OF CSF TAU (2019) (0)
- Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease (2022) (0)
- The role of CSF biomarkers in the diagnosis of frontotemporal dementia: New criteria offer new insights (2013) (0)
- IC-P-093 Fluid registration derived hippocampal atrophy rates: Reliability and comparison with manual measures, a methodological approach (2006) (0)
- Oral Sessions: O3-03: Biomarkers: Temporal Sequence of Biomarkers (2013) (0)
- P453 Electroencephalography (EEG) and magnetic resonance imaging (MRI) in Alzheimer's dementia (AD) (1996) (0)
- Axonal damage and astrocytosis are biological correlates of grey matter network integrity loss: a cohort study in autosomal dominant Alzheimer disease (2023) (0)
- A dutch family with autosomal dominant pure spastic paraparesis (strümpell-lorrain) (1990) (0)
- S2-02-01 MRI and CSF analysis probe different stages of AD and have complementary value (2007) (0)
- Quantitative accuracy and 28-day test-retest repeatability of parametric methods for [11C]UCB-J PET (2021) (0)
- Interhemispheric coherence during different attentional conditions in dichotic listening task (2001) (0)
- GRANULOCYTES: KEY PLAYERS IN PERIPHERAL Aβ CLEARANCE? (2017) (0)
- CORRELATION OF CORTICAL THICKNESS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2016) (0)
- RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO Aβ, APOE ε4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY (2018) (0)
- Amyloid discordance analysis in cognitively normal monozygotic twins demonstrates that the memory domain is affected first in preclinical AD (2021) (0)
- Clinical value of amyloid imaging. The Dutch experience (2014) (0)
- Canagrincerebrospinalfluidconcentrationbeusedasanearlybiomarker for Alzheimer's disease? (2015) (0)
- Different patterns of cortical atrophy in early- and late-onset Alzheimer's disease (2012) (0)
- PANEL DISCUSSION (2019) (0)
- CORRELATION OF CORTICAL THICKNESS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2016) (0)
- Subjective cognitive decline and self‐reported sleep at a memory clinic: The SCIENCe project (2021) (0)
- WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS (2018) (0)
- P1-302: Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease (2008) (0)
- The impact of COVID‐19 restrictions after one year on modifiable risk factors related to brain health in older adults in The Netherlands (2022) (0)
- JAMA Paper supplement (2015) (0)
- Value of plasma biomarkers to predict memory change in cognitively unimpaired individuals (2022) (0)
- Dementias with Associated ‘Brain Swelling’ (2011) (0)
- P3-029 Pattern of cognitive impairment in AD is modified by APOE genotype (2006) (0)
- Pronounced regional spectral, connectivity and network changes reflect visual deficits in posterior cortical atrophy: An EEG study on PCA (2020) (0)
- Heterogeneity of White Matter Hyperintensities in Alzheimer's Disease: Post-Mortem Quantitative MRI and Neuropathology (2009) (0)
- IC-P1-015: Random brain networks in Alzheimer's disease (2008) (0)
- Cognitive dysfunction in multiple sclerosis (2005) (0)
- Reproducibility of EEG functional connectivity in Alzheimer’s disease (2020) (0)
- Pathway‐specific polygenic risk score of AD‐associated genetic variants associated with AD risk, resilience against AD, and progression to AD (2021) (0)
- Cerebrovascular and Alzheimer's disease: A synergistic pathogenesis (2013) (0)
- P3-022 Biobanking in AD and related disorders- the Amsterdam experience (2004) (0)
- CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME (2014) (0)
- APOE-ε4 allele and neuropsychiatric symptoms in MCI: findings from the DESCRIPA study (2011) (0)
- Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer ' s disease (2019) (0)
- ADDED DIAGNOSTIC VALUE OF 18F-FLUTEMETAMOL PET SCANNING IN YOUNG PATIENTS WITH DEMENTIA (2019) (0)
- S5-01-03: Added value of neuroimaging to diagnosis of AD (2006) (0)
- Characterization of the behavioral and dysexecutive variants of Alzheimer's disease (2015) (0)
- The Souvenir II study: Rationale and study design (2011) (0)
- ELECTRO-ENCEPHALOGRAPHY AS A PRODROMAL MARKER OF DEMENTIA WITH LEWY BODIES (2018) (0)
- IC-P-020 MRI biomarkers as predictors of mortality in dementia (2006) (0)
- CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE) (2017) (0)
- No proof for retinal amyloid after oral curcumin in amyloid confirmed AD cases (2021) (0)
- Widespread disruption of functional brain organization in people with early-onset Alzheimer's disease (2013) (0)
- [Doctor, is my mother suffering from dementia?] (2017) (0)
- MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY (2018) (0)
- EARLY TAU PET PATHOLOGY IS ASSOCIATED WITH MEMORY PERFORMANCE IN COGNITIVELY UNIMPAIRED INDIVIDUALS WITH SCD: THE SCIENCE PROJECT (2019) (0)
- P3-063 Activation in the working memory network in healthy aging, mild cognitive impairment and Alzheimer's disease (2004) (0)
- Chapter 3 Arterial stiffness , progression of brain atrophy and vascular brain lesions (2013) (0)
- Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease (2015) (0)
- Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test? (2020) (0)
- Assessment of microglial activation in patients with Alzheimer's disease using [C-11]-(R)-PK11195 and PET (2005) (0)
- LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER’S DISEASE (2018) (0)
- ATROPHY PATTERNS PREDICTING COGNITIVE DECLINE IN NON-DEMENTED SUBJECTS ARE INDEPENDENT OF AMYLOID PATHOLOGY (2016) (0)
- Response to an acute pharmacological challenge with galantamine as a predictor for responsiveness to long-term treatment (2013) (0)
- Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2020) (0)
- Sex differences in CSF biomarkers vary by Alzheimer ’ s disease stage and APOE ε 4 1 genotype 2 3 (2020) (0)
- IC-P3-177: An automated method for measuring longitudinal volume changes of the ventricular system (2008) (0)
- Subject Index Vol. 21, 2006 (2006) (0)
- RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE (2014) (0)
- Reply from the authors [4] (2006) (0)
- Cerebral blood flow, measured with ASL perfusion MRI at 3T, and structural brain changes in Alzheimer's disease (2012) (0)
- Neurofilament light chain cannot be measured in urine to distinguish frontotemporal dementia with primary psychiatric diseases (2022) (0)
- Neuropathological hallmarks of Alzheimer’s disease in centenarians, in the context of aging (2021) (0)
- F1â•’01â•’04: DEMENTIA WITH LEWY BODIES (2018) (0)
- Sikkes A composite measure of cognitive and functional progression in Alzheimer ’ s disease : design of the Capturing Changes in Cognition ( Catch-Cog ) study Alzheimer (2019) (0)
- DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER’S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER’S DISEASE: THE VALUE OF NEUROIMAGING (2019) (0)
- MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNG-ONSET DEMENTIA (2018) (0)
- CHARACTERIZATION OF SUSPECTED NON-ALZHEIMER’S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING (2017) (0)
- Differential influence of age at onset on the effect of white matter hyperintensities and global atrophy on cognition in Alzheimer's disease (2010) (0)
- ACTIVE AND PASSIVE RESERVE DIFFERENTIALLY MITIGATE COGNITIVE SYMPTOMS IN DEMENTED AND NON-DEMENTED STAGES OF ALZHEIMER’S DISEASE (2016) (0)
- THE FUTURE OF CARE: THE DIGITAL ALZHEIMER CENTER–EVALUATION OF AN ONLINE PORTAL FOR PATIENTS WITH DEMENTIA AND THEIR INFORMAL CAREGIVERS (2014) (0)
- Résultats d’efficacité, de tolérance et des biomarqueurs de SCarlet RoAD—une étude de phase 3 internationale du gantenerumab chez des patients atteints d’une maladie d’Alzheimer (MA) à la phase prodromale (2016) (0)
- Detecting Alzheimer pathology in vivo: Comparing regional binding of [11C]PIB and [18F]FDDNP (2008) (0)
- Cross-cultural differences in instrumental activities of daily living (IADL): Translations and adaptations of the amsterdam iadl questionnaire (2015) (0)
- EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES (2018) (0)
- The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial (2014) (0)
- Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias (2021) (0)
- Can agrin CSF concentration be used as an early biomarker for Alzheimer ’ s disease ? (2015) (0)
- Plasma Amyloid (A42) Correlates with CSF A42 in Alzheimer’s Disease (2018) (0)
- Current status and quantitative results of the AMYPAD prognostic and natural history study (2021) (0)
- PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM (2017) (0)
- Erratum: Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (Scientific reports (2017) 7 1 (8899)) (2018) (0)
- The majority of the patients with a monogenic predisposition for dementia did not fulfill current criteria for genetic testing (2021) (0)
- Do microbleeds predict stroke in Alzheimer's disease (MISTRAL)? Study design and first results (2013) (0)
- Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline (2017) (0)
- PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS (2017) (0)
- Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins (2020) (0)
- CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER’S DISEASE COMPARED TO CONTROLS (2018) (0)
- CSF and MRI biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer's disease (2010) (0)
- Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer’s disease (2015) (0)
- Circadian Rest-Activity Alzheimer' s Disease Rhythm Disturbances in (1996) (0)
- FACTORS PREDICTING MORTALITY AT THE MEMORY CLINIC AT SIRIRAJ HOSPITAL: 815 THAI COHORT (2018) (0)
- PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER’S PATIENTS AND CONTROLS USING FLORTAUCIPIR (2017) (0)
- COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS (2014) (0)
- Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes (2022) (0)
- Predictors of time to AD diagnosis in subjects with MCI (2010) (0)
- Diagnostic impact of biomarkers including CSF and PET in a tertiary memory clinic (2015) (0)
- Functional segregation of medial temporal lobe activation during encoding and recognition of visuospatial scenes (2000) (0)
- Distinct patterns of atrophy in postmortem-confirmed dementias (2015) (0)
- ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS (2018) (0)
- Study partner‐ and self‐reported difficulties in cognitively complex everyday activities in participants without objective cognitive impairment (2020) (0)
- DECISION TREE ANALYSIS REVEALS TWO CUT-OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS (2017) (0)
- INCREASED CSF AMYLOID-β 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY (2018) (0)
- The development of a new IADL informant-based questionnaire: The Amsterdam IADL questionnaire (2010) (0)
- Testing causality in the association between amyloid‐β and tau in genetically identical twins (2022) (0)
- Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status (2021) (0)
- DETECTING ALZHEIMER’S DISEASE AT DIFFERENT LEVELS OF WHITE-MATTER HYPERINTENSITIES USING MRI (2019) (0)
- NOVEL ULTRASENSITIVE IMMUNOASSAY DETECTING P-TAU THR217 COMPLETELY DISTINGUISHES ALZHEIMER’S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATION (2018) (0)
- IC-P3-211: Increased randomness of functional brain networks in AD: ‘Small-world' network analysis of non-linear functional connectivity (2008) (0)
- Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting (2013) (0)
- Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results (2018) (0)
- Psychotic symptoms and formal thought disorders in behavioral variant frontotemporal dementia (2016) (0)
- THE DIAGNOSTIC FRAMEWORK FOR ALZHEIMER'S DISEASE (2019) (0)
- MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE (2014) (0)
- AN OCCUPATIONAL HISTORY IN THE TRANSPORTATION AND LOGISTICS SECTOR IS RELATIVELY COMMON AMONG INDIVIDUALS WITH VASCULAR DEMENTIA (2019) (0)
- WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS (2014) (0)
- ATYPICAL ALZHEIMER’S GREAT EXPECTATIONS FROM THE UNEXPECTED NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER’S DISEASE (2019) (0)
- Subject Index Vol. 24, 2007 (2007) (0)
- EFFECT OF APOE-ε2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER’S DISEASE (2017) (0)
- STEPWISE PATIENT SELECTION FOR AMYLOID MEASUREMENTS (2019) (0)
- The trajectory of cognitive decline in preclinical dementia in people attending a memory clinic: The 4C-MCI study (2013) (0)
- Contents Vol. 41, 2016 (2016) (0)
- Resilience and resistance to the accumulation of amyloid plaques and neurofibrillary tangles in centenarians: An age-continuous perspective. (2022) (0)
- WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2017) (0)
- Immune response and endocytosis pathways are associated with the escape of Alzheimer’s Disease (2019) (0)
- P3-036 Clinical correlates of CSF Aβ42 and tau in patients with mild cognitive impairment (2004) (0)
- ACTIVE AND PASSIVE RESERVE DIFFERENTIALLY MITIGATE COGNITIVE SYMPTOMS IN DEMENTED AND NON-DEMENTED STAGES OF ALZHEIMER’S DISEASE (2016) (0)
- Interference of cognitive disorders in everyday life: The diagnostic accuracy of a new Instrumental Activities of Daily Living instrument (2013) (0)
- Early-onset Alzheimer's disease patients show distinct changes in oscillatory brain dynamics (2011) (0)
- Increase in CSF F2-isoprostanes is related to cognitive decline in APOE4 carriers (2015) (0)
- Author and Subject Index (1998) (0)
- Discordant amyloid-β PET and CSF biomarkers and its clinical consequences (2019) (0)
- WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS (2018) (0)
- CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS (2014) (0)
- AMYLOID LEVELS IN THE NORMAL RANGE ARE PREDICTIVE FOR INCIDENT DEMENTIA IN NON-DEMENTED ELDERLY (2016) (0)
- EARLY ALTERATIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS (2017) (0)
- Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline (2021) (0)
- CSF AMYLOID BETA 1-42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSIS-DEPENDENT UPWARD DRIFT (2017) (0)
- EUROPEAN PERSPECTIVE ON CLINICAL AMYLOID IMAGING (2018) (0)
- Plasma amyloid‐β oligomerization assay as a screening test for abnormal amyloid status (2020) (0)
- P66-F Resting-state source-space MEG detects hippocampal hyperactivity in amyloid-positive amnestic MCI (2019) (0)
- VIVIAD, A Phase 2b Study Investigating Varoglutamstat in Patients with MCI and Mild AD: Dose Selection and Interim Safety Results (2022) (0)
- O1-02-06 Deactivation in healthy aging, mild cognitive impairment and Alzheimer's disease (2004) (0)
- P.5.b.001 Longitudinal [11C]PIB and [18F]FDDNP PET studies on memory in patients and controls (2010) (0)
- Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs (2017) (0)
- DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT (2017) (0)
- LONGITUDINAL DYNAMIC [18F]FLORTAUCIPIR PET REVEALS INCREASED EARLY STAGE TAU PATHOLOGY IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE (2019) (0)
- The increase of BRI2 in early stages of Alzheimer's disease correlates with reduced levels of ADAM10 and may prevent its binding to APP (2013) (0)
- Memory functions of the perirhinal and parahippocampal cortices of the human medial temporal lobe (2003) (0)
- Understanding (endo)phenotypical heterogeneity: The role of age and APOE (2012) (0)
- CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE (2014) (0)
- Magnetic resonance imaging in the diagnosis of dementia in a unselected population of elderly individuals. Preliminary results from the AMSTEL project (1992) (0)
- DEVELOPMENT OF NEW BIOMARKERS FOR ALzHEIMER’S DISEASE (2011) (0)
- VASCULAR AND CLINICAL CORRELATES OF MICROBLEEDS IN PRODROMAL AD (2014) (0)
- Steeper memory decline after COVID-19 lockdown measures (2023) (0)
- Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment (2020) (0)
- Evaluation of partial volume corrections for (R)-[C-11]PK11195 studies (2007) (0)
- NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT? (2018) (0)
- Steps towards the implementation of amyloid‐PET in memory clinics: AMYPAD Diagnostic and Patient Management Study (2022) (0)
- PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER’S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT (2018) (0)
- Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands (2015) (0)
- Chapter 4 Detection of Alzheimer pathology in vivo using both [ 11 C ] PIB and [ 18 F ] FDDNP positron emission tomography (2011) (0)
- P1-248: Diagnostic utility of cross-sectional and longitudinal hippocampal volumetry in memory clinic patients (2008) (0)
- SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER’S DISEASE (2017) (0)
- P3-046: Predicting dementia using instrumental activities of daily living in the development of screening guidelines and diagnostic criteria for predementia Alzheimer's disease study (2008) (0)
- PET imaging in dementia: future prospects (2008) (0)
- Cognitive correlates of CSF biomarkers in Frontotemporal dementia (2014) (0)
- Dementia risk communication. A user manual for Brain Health Services—part 3 of 6 (2021) (0)
- 1 Variability in longitudinal CSF Tau and P-Tau measurements (2011) (0)
- Podium Presentations: Wednesday, July 25, 2018 P1394 F4-07-04 THE CONSEQUENCES OF TAU IN THE LOCUS COERULEUS ON ALZHEIMER’S DISEASE (2018) (0)
- A systematic review of IADL scales in dementia : Room for improvement CHAPTER 4 (2011) (0)
- Neuroproteomics of cognitively healthy centenarians in the context of aging and Alzheimer’s disease (2021) (0)
- Physical activity is associated with improved executive function and processing speed: The LADIS Study (2013) (0)
- Visual assessment of parametric [11C]PIB images (2012) (0)
- Detecting progranulin mutations in people with atypical Alzheimer's disease (2013) (0)
- Independent information from PET, CSF and plasma biomarkers of tau pathology in Alzheimer’s disease (2021) (0)
- DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER\textquotesingleS DISEASE PATHOLOGY AND PROGRESSION (2017) (0)
- Author response for "Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow‐up" (2021) (0)
- LONGITUDINAL DYNAMIC [18F]FLORTAUCIPIR PET REVEALS INCREASED EARLY STAGE TAU PATHOLOGY IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE (2019) (0)
- end-organ damage for function of the peripheral vasculature: implications Effects of central arterial aging on the structure and (2015) (0)
- A RE-EVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS (2014) (0)
- APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease (2020) (0)
- NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN (2014) (0)
- Visual rating of hypointensities in the brain using susceptibility-weighted Imaging; a pilot study (2011) (0)
- CSF proteomic profiling of mild cognitive impairment individuals with suspected nonâ•’Alzheimerâ•Žs disease pathophysiology: Developing topics (2020) (0)
- IMPAIRMENT IN COMPLEX ACTIVITIES OF DAILY LIVING IS RELATED TO NEURODEGENERATION IN ALZHEIMER’S DISEASE SPECIFIC REGIONS (2018) (0)
- Contents Vol. 21, 2006 (2006) (0)
- Social cognition provides early distinction between phenocopy syndrome of behavioural variant frontotemporal dementia and behavioural variant frontotemporal dementia (2021) (0)
- Total macular thickness correlates with parietal cortical atrophy on MRI in early onset Alzheimer’s disease (2017) (0)
- ATN BIOMARKER MODEL AS A DETERMINANT OF COGNITIVE DECLINE AND INCIDENT CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE: THE SCIENCE PROJECT (2019) (0)
- IMPACT ON COGNITION IN PERSONS WITH NORMAL COGNITION, MCI, AND DEMENTIA (2014) (0)
- Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage Neuroimaging (2015) (0)
- Increase in cerebrospinal fluid F2-isoprostanes is related to clinical decline in apolipoprotein E-ε4 carriers but not in non-carriers (2012) (0)
- Neuropathological assessment of cognitively healthy centenarians - The 100-Plus Study (2017) (0)
- Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- CHAPTER 2 The level of physical activity and executive functioning in early-onset dementia (2014) (0)
- Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non‐demented memory clinic participants (2020) (0)
- Patterns of atrophy in Alzheimer's disease: Does cognition follow structure? (2012) (0)
- THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE (2017) (0)
- White Matter Disease: 2nd Symposium of the European Task Force on Age-Related White Matter Disorders, Amsterdam, May 1997: Proceedings (1998) (0)
- Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: the NUDAD project (2020) (0)
- PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER’S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE (2017) (0)
- Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme control analysis of Alzheimer’s disease (2018) (0)
- Sex-specific metabolic pathways associate with Alzheimer's Disease (AD) endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery (EMIF-AD MBD) cohort (2021) (0)
- Validation of reference regions for [F-18]Flortaucipir and [F-18]Florbetapir brain PET studies using non-invasive simplified metrics (2019) (0)
- Biomarker testing in MCI patients—deciding who to test (2020) (0)
- Resilience and resistance to Alzheimer's disease-associated neuropathological substrates in centenarians: an age-continuous perspective (2022) (0)
- Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort (2021) (0)
- Partial volume corrected image derived input functions for kinetic modelling of FDG PET brain studies (2019) (0)
- Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- The escape from Alzheimer's disease underlies genetic variants involved into immune response and endocytosis pathways (2019) (0)
- 7T T2∗-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD (2014) (0)
- Distinct patterns of atrophy in postmortem confirmed dementias (2015) (0)
- Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- Which biomarkers are useful in predicting converters to Alzheimer's Disease from MCI at 12 or 36 months from baseline? (2011) (0)
- Rationale and design of the “NEurodegeneration: Traumatic brain injury as Origin of the Neuropathology (NEwTON)” study: a prospective cohort study of individuals at risk for chronic traumatic encephalopathy (2022) (0)
- LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS (2018) (0)
- The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics (2018) (0)
- Monozygotic twin similarities for AD biomarkers: the Twin60+study (2018) (0)
- EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL b -AMYLOID DEPOSITION IN THE BRAIN PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A)INALZHEIMER’S DISEASE:INITIAL (2018) (0)
- Amyloid and Microbleeds in different dementias: retained or drained? (2011) (0)
- Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline (2018) (0)
- [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE (2017) (0)
- EUSI-ESO News (2008) (0)
- LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS (2018) (0)
- A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study (2021) (0)
- IC-P-051 White matter hyperintensity load is a possible predictor of corpus callosum atrophy in the elderly: The LADIS study (2006) (0)
- A PLASMA PHOSPHOLIPID BIOMARKER PROFILE FOR DETECTING PRECLINICAL ALZHEIMER'S DISEASE CAN BE MODIFIED BY ORAL INTAKE OF NUTRIENTS THAT INCREASE PHOSPHOLIPID SYNTHESIS (2014) (0)
- Cerebral perfusion: arterial spin-labeling MRI (2014) (0)
- Identifying and characterizing patterns of functional decline in memory clinic patients (2021) (0)
- O1-02-01: Progression of mild cognitive impairment to dementia: The contribution of atrophy and vascular disease (2008) (0)
- Relationship between clinical symptomatology and disease burden in dementia with Lewy bodies: An overview of the DEvELOP baseline results (2020) (0)
- Synaptic proteins relate to memory scores in preclinical Alzheimer’s disease and cognitively healthy controls depending on amyloid (2020) (0)
- CEREBRAL BLOOD FLOW MEASURED WITH PHASE-CONTRAST MRI IN AD, MCI AND CONTROLS (2016) (0)
- The Impact of Amyloid PET Disclosure on Quality of Life in Patients With Young Onset Dementia (2021) (0)
- The Alzheimer’s disease drug development landscape (2021) (0)
- A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER’S DISEASE (2019) (0)
- PREVALENCE OF VASCULAR RISK FACTORS IN DIFFERENT STAGES OF PRODROMAL ALZHEIMER’S DISEASE AND ITS INFLUENCE ON COGNITIVE DECLINE (2016) (0)
- Biomarkers in dementia (2011) (0)
- The correlation between neuropathology levels and cognitive performance in centenarians. (2023) (0)
- Chapter 15 Advances in Neuroimaging (2007) (0)
- Chapter 2 . 1 Heterogeneous language profiles in patients with Primary Progressive Aphasia due to Alzheimer ’ s disease (2016) (0)
- Publisher Correction: LifeTime and improving European healthcare through cell-based interceptive medicine (2021) (0)
- IC-P2-144: Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease (2008) (0)
- WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS (2014) (0)
- DIFFERENT PATHOLOGICAL DISTRIBUTION PATTERN OF PHOSPHORYLATED TAU AND MICROGLIA IN AMNESTIC AND NON-AMNESTIC ALZHEIMER’S DISEASE (2016) (0)
- Subject Index Vol. 19, 2005 (2005) (0)
- BIOMARKER-BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE (2017) (0)
- Contents Vol. 35, 2013 (2013) (0)
- The plasma peptides of breast versus ovarian cancer (2019) (0)
- The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors (2015) (0)
- [Amyloid-plaque imaging of the brain using PET]. (2011) (0)
- CEREBRAL BLOOD FLOW MEASURED WITH PHASE-CONTRAST MRI IN AD, MCI AND CONTROLS (2016) (0)
- CAPTURING CHANGES IN EVERYDAY FUNCTIONING (2014) (0)
- DOES BRAIN AMYLOID DEPOSITION IMPACT EVERYDAY FUNCTIONING IN SUBJECTS WITH COGNITIVE COMPLAINTS? RESULTS FROM THE INSIGHT COHORT (2017) (0)
- Contents Vol. 20, 2005 (2005) (0)
- Effects of Oral ALZ‐801, an Amyloid Oligomer Inhibitor, on Plasma Biomarkers in APOE4 Carriers with Early Alzheimer’s Disease: Results of Six‐month Interim Analysis from a Phase 2 Biomarker Study (2022) (0)
- Early detection of Alzheimer’s disease in the human retina: insights of 7 years research (2023) (0)
- LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY (2014) (0)
- DISCOVERY AND VALIDATION OF PLASMA BIOMARKERS RELATING TO CSF MEASURES OF ALZHEIMER'S DISEASE PATHOLOGY (2014) (0)
- IN VITRO CHARACTERIZATION OF TAK-071: A NOVEL MUSCARINIC M 1 RECEPTOR-POSITIVE ALLOSTERIC MODULATOR WITH LOW COOPERATIVITY THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH CYCLIC D-ENANTIOMERIC PEPTIDE TARGETING AMYLOID-BETA IN ALZHEIMER’S DISEASE (2017) (0)
- Clusterin and ApoE as biomarkers for neurodegenerative disease , and their role in the etiology of Alzheimer ’ s disease (2014) (0)
- IC-P2-140: Progression of MCI to dementia: The contribution of atrophy and vascular disease (2008) (0)
- The role of ASL-measured cerebral blood flow in the differential diagnosis of Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies (2013) (0)
- Identification of plasma proteome signatures associated with ATN framework using SOMAscan (2020) (0)
- The plasma peptides of ovarian cancer (2018) (0)
- Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer’s disease: A retrospective cohort study (2015) (0)
- Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project (2019) (0)
- CSF biomarkers predict progression in patients with subjective memory complaints (2011) (0)
- Basic clinical knowledge (2008) (0)
- CONCORDANCE OF [18F]FLUTEMETAMOL AMYLOID DEPOSITION IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2016) (0)
- Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients (2017) (0)
- Responding to responsive behaviour in Alzheimer's disease – Author's reply (2021) (0)
- P2-308 Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression: The LADIS study (2006) (0)
- Effectiveness and costs-effectiveness of post-diagnosis treatment in dementia coordinated by memory clinics in comparison to treatment coordinated by general practitioners (2011) (0)
- P2-295 White matter hyperintensity load is a possible predictor of corpus callosum atrophy in the elderly: The LADIS study (2006) (0)
- PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE (2018) (0)
- APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD (2014) (0)
- Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease (2020) (0)
- DNA methylation differences associated with peripheral biomarkers in the EMIF‐AD cohort (2020) (0)
- RISK FACTORS FOR COGNITIVE DECLINE ARE AGE DEPENDENT (2016) (0)
- MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA (2014) (0)
- Biomarkers in neurodegenerative diseases: The Dutch Parelsnoer Initiative (2011) (0)
- 3 . 2 Resting-state connectivity in mild cognitive impairment and Alzheimer ’ s disease (2012) (0)
- COGNITIVELY NORMAL APOE-ε2 HOMOZYGOTES DISPLAY GREATER HIPPOCAMPI: AN UNBIASED VOXEL-BASED ANALYSIS (2019) (0)
- Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6 (2021) (0)
- Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6 (2021) (0)
- P3-098: Whole-brain atrophy rate and CSF biomarker levels in mild cognitive impairment and Alzheimer's disease: A longitudinal study (2008) (0)
- Patients With Mild Cognitive Impairment CSF Biomarkers and Incipient Alzheimer Disease in Supplementary material (2009) (0)
- P4-305 IMPACT OF SIMVASTATIN ON CEREBRAL BLOOD FLOW, PULSATILITY INDEX, AND ALZHEIMER’S DISEASE BIOMARKERS: A CLINICALTRIAL (0)
- CSF proteomic changes in pre‐preclinical Alzheimer’s disease: A monozygotic twin study (2020) (0)
- O1-03-01 Microglial activation in patients with mild cognitive impairment and Alzheimer’s disease: A study using [11C](R)-PK11195 and PET (2006) (0)
- A changing diagnostic paradigm of Alzheimer’s disease; an introduction to IWG and NIA‐AA criteria (2022) (0)
- THE AMYPAD-DX CONTROLLED TRIAL ON THE DIAGNOSTIC VALUE OF AMYLOID PET (2017) (0)
- P3-061 Effects of galantamine on brain activation during episodic memory in Alzheimer's disease (2004) (0)
- The “rights” of precision drug development for Alzheimer’s disease (2019) (0)
- [Atypical pain in the mandible caused by trigeminal neuralgia]. (2008) (0)
- Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings (2014) (0)
- NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER’S DISEASE (2019) (0)
- Aging and Alzheimer ’ s disease have a diverse effect on restingstate EEG functional connectivity (0)
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials (2016) (0)
- First results of the AMYPAD Prognostic and Natural History Study: amyloid‐PET Centiloid predicts cognitive functioning in a pre‐dementia population (2022) (0)
- IC-P2-145: Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study (2008) (0)
- EEG abnormalities in early- and late-onset Alzheimer's disease: Evidence for the existence of subtypes (2010) (0)
- MAGNETIC RESONANCE IMAGING HYPERINTENSITIES IN ALZHEIMER'S DISEASE. AUTHOR'S REPLIES (1991) (0)
- A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease (2021) (0)
- A prediction rule of CSF biomarkers for Alzheimer's disease in clinical practice (2011) (0)
- miRNA expression in cerebrospinal fluid of Alzheimer's disease patients (2012) (0)
- P37-18 Resting-state brain dynamics and white matter hyperintensities (2010) (0)
- Intracranial ganglioglioma: MR imaging. (1990) (0)
- Quantitative regional validation of the rating scale for posterior cortical atrophy (2013) (0)
- A data‐driven latent atrophy factor model reveals differential associations between relative frontal atrophy patterns and specific neuropsychiatric symptoms in Alzheimer’s disease (2021) (0)
- Widespread disruption of functional brain organization in early-onset Alzheimer's disease patients (2013) (0)
- Effects of ALZ-801, an Oral Amyloid Oligomer Inhibitor, on Biomarkers of Alzheimer’s Disease (AD): 12-Month Results of Phase 2 Biomarker Study in Early AD (S26.007) (2023) (0)
- 1 NIAAA Research Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 11-2 7-17 3 4 (2017) (0)
- NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY (2018) (0)
- [Early diagnosis of Alzheimer disease: the role of Positron Emission Tomography (PET)]. (2013) (0)
- Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter? (2021) (0)
- Chronische traumatische encefalopathie (2017) (0)
- A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease (2017) (0)
- Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression (2015) (0)
- Current status and quantitative results of the AMYPAD prognostic and natural history study (2020) (0)
- Normalized brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer ’ s disease (2014) (0)
- A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer’s disease (2015) (0)
- Diagnostic Assessment & Prognosis Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease (2016) (0)
- P1-246: White matter hyperintensities in Alzheimer patients and non-demented elderly: Postmortem quantitative MRI and neuropathological characteristics (2008) (0)
- Regional functional connectivity changes in AD and MCI: dual regression applied to resting state fMRI (2011) (0)
- PREFRONTAL CORTEX TRANSCRIPTOME BY MULTIPLE RNA-SEQUENCING (2013) (0)
- TauRUS Tau-PET Atlas (MNI space, 1 mm) (2018) (0)
- Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum (2021) (0)
- Anxiety is related to Alzheimer's disease markers in cerebrospinal fluid of subjects with mild cognitive impairment (2011) (0)
- Different patterns of cortical atrophy in early- and late-onset Alzheimer's disease (2012) (0)
- Book Reviews (2000) (0)
- GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS (2016) (0)
- Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies (2019) (0)
- GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER’S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE (2019) (0)
- CSF AD-PROFILE IN DEMENTIA WITH LEWY BODIES: EFFECT ON CLINICAL PARAMETERS AND COGNITIVE DECLINE (2014) (0)
- Neuropsychological profiles in behavioural variant Frontotemporal Dementia and Psychiatric disorders (2016) (0)
- EFFECT OF APOE ε2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER’S DISEASE (2017) (0)
- BDNF‐Met polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: The SCIENCe Project (2020) (0)
- Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data (2015) (0)
- Distribution of tau pathology and neuroinflammation in typical versus atypical non-amnestic Alzheimer's disease (2017) (0)
- CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE (2014) (0)
- Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly (2015) (0)
- P4-525 DATA-DRIVEN TAU-PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER’S DISEASE (2017) (0)
- The Tower of London test adapted for fMRI. (1998) (0)
- Plasma P‐tau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years (2021) (0)
- Prevalence of Amyloid-Related Imaging Abnormalities in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Findings from Ongoing Clinical Trials of Oral Anti-Amyloid Agent ALZ-801 (Valiltramiprosate) (P5-6.003) (2023) (0)
- Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study (2018) (0)
- VCI: What's in a name?— Prevalence of vascular abnormalities on MRI in a memory clinic population (2012) (0)
- Contents Vol. 29, 2010 (2010) (0)
- Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings (2020) (0)
- Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer’s disease pathology (2016) (0)
- GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER’S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE (2019) (0)
- Cross‐modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease (2020) (0)
- Dutch Brain Research Registry for online study participant recruitment: Design and first results (2020) (0)
- Cerebrospinal fluid tau levels indicate aberrant neuronal plasticity in Alzheimer disease (2020) (0)
- Examining centiloid quantification against visual assessment using [18F]flutemetamol PET (2020) (0)
- Erratum (1992) (0)
- Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2018) (0)
- The medical food Souvenaid preserves functional brain network organisation in patients with mild Alzheimer's disease (2012) (0)
- Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer’s disease polygenic risk score (2022) (0)
- 456 Qualitative assessment of cerebral atrophy on MRI. Inter- and intro-observer reliability in dementia and normal aging (1996) (0)
- Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins (2020) (0)
- Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease (2022) (0)
- A STUDY TO EVALUATE THE KINETICS AND 28 DAY TEST-RETEST REPEATABILITY AND REPRODUCIBILITY OF THE RADIOLIGAND [11C]UCB-J FOR BRAIN PET IMAGING IN HEALTHY SUBJECTS AND MILD-MODERATE ALZHEIMER’S DISEASE SUBJECTS (2019) (0)
- Capturing functional change in early Alzheimer’s disease: Comparing instruments and scoring techniques to detect subtle decline (2021) (0)
- Increased microglial activation in MCI and AD: An (R)-[11C]PK11195 PET study (2010) (0)
- Predicting institutionalization and mortality across the spectrum of Alzheimer’s disease (2021) (0)
- A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing (2022) (0)
- Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release (2020) (0)
- AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA (2017) (0)
- Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia (2018) (0)
- Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [18F]flortaucipir, [11C]UCB‐J and magnetoencephalography study (2020) (0)
- Added diagnostic accuracy after flutemetamol PET scanning in young patients with dementia in an academic memory clinic setting (2021) (0)
- P3-096 Effects of galantamine challenge on episodic and working memory systems in patients with mild cognitive impairment: an FMRI study (2004) (0)
- Neuropsychiatric symptoms associated with the APOE-ε4 allele in subjects with mild cognitive impairment in the DESCRIPA and ADNI cohorts (2012) (0)
- PARAMETRIC IMAGING OF [18F]FLORBETAPIR: A TEST-RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER’S DISEASE (2018) (0)
- Microglial activation in healthy aging (2010) (0)
- Sphingolipids in Cerebrospinal Fluid and Plasma Lipoproteins of APOE4 Homozygotes and Non-APOE4 Carriers with Mild Cognitive Impairment versus Subjective Cognitive Decline (2023) (0)
- CHAPTER 3 Clinical significance of patient selection in Alzheimer ’ s disease using baseline MRI (2011) (0)
- Protein kinase activity profiling on cerebrospinal fluid to find diagnostic biomarkers for Alzheimer's disease (2012) (0)
- CSF beta-amyloid 1-42, but not CSF tau, phosphorylated tau or hippocampal atrophy on MRI relate to Alzheimer's disease pathology load in the brain (2013) (0)
- Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies (2020) (0)
- Discovery of peripheral biomarkers of alzheimer'/INS;s disease pathology (2013) (0)
- Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease (2018) (0)
- Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- Kinetics and 28 day test-retest repeatability and reproducibility of [C-11]UCB-J brain PET imaging (2019) (0)
- Patients to learn from: on the need for systematic integration of research and care in academic health care (2017) (0)
- Relation between APOE ε4 allele and MCI is modulated by geographical region: Results from the DESCRIPA study (2009) (0)
- COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER’S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY (2018) (0)
- Miscellaneous Forms of Dementia (2002) (0)
- Grey zone amyloid burden heralds future memory decline: The SCIENCe Project (2020) (0)
- LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS (2018) (0)
- Contents Vol. 8, 2011 (2011) (0)
- THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT (2017) (0)
- P3-030 Correlation between CSF levels of Tau, PTau-181, and Abeta42 and the score on the predementia Alzheimer's disease scale (PAS) in subjects with MCI (2004) (0)
- Cortical analysis using 7T MR phase images reveals regional differences between early and late onset Alzheimer’s disease (2014) (0)
- Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- The ‘CSF Alzheimer’s profile’: Easily said, but what do we mean? (2013) (0)
- [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER’S DISEASE SPECTRUM (2018) (0)
- Title ( 82 / 100 characters ) : Neurogranin as cerebrospinal fluid biomarker for dementia-assay comparison study (2018) (0)
- Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants (2020) (0)
- O1-05-01: Biomarker profiles and their relationship to cognitive and other clinical variables in Alzheimer's disease (2008) (0)
- PLASMA AMYLOID BETA 1-42 AND 1-40 MEASURED BY A NOVEL SIMOA ASSAY AS A DIAGNOSTIC TOOL FOR ALZHEIMER'S DISEASE PATHOLOGY (2019) (0)
- P3-100: Variability in longitudinal CSF Tau and phosporylated Tau measurements (2008) (0)
- Chapter 2 . 1 Different patterns of gray matter atrophy in early and late-onset AD (2015) (0)
- Application of peripheral electrical stimulation in Alzheimer's disease reconsidered (2004) (0)
- Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial (2021) (0)
- The plasma peptides of Alzheimer’s disease (2021) (0)
- SPECIFIC COGNITIVE IMPAIRMENTS (2018) (0)
- Loss of corpus callosum tissue is associated with subjective memory complaints: The LADIS study (2010) (0)
- The Lancet Neurology Amyloid and FDG-PET in the diagnostic work-up of Alzheimer’s disease and other dementias (2020) (0)
- Selective vulnerability of the GABRQ-expressing population in the anterior cingulate cortex in frontotemporal dementia (2020) (0)
- 68 Cerebral microbleeds: identification, prevalence and clinical relevance (2012) (0)
- EVIDENCE THAT ORAL P38 MAPK ALPHA ANTAGONISM IMPROVES EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE (AD) (2017) (0)
- Predicting cognitive outcome using the preclinical AD scale (PAS) (2000) (0)
- Man with subjective complaints but abnormal CSF (2011) (0)
- P2-131 Feasibility and usefulness of longitudinal beta-amyloid1-42 levels in CSF of patients with various cognitive and neurological disorders (2006) (0)
- CSF biomarkers predict cognitive decline in Alzheimer's disease (2009) (0)
- Secondary prevention of Alzheimer’s dementia: neuroimaging contributions (2018) (0)
- Heterogeneity of atrophy patterns in mild cognitive impairment and relationship to CSF biomarkers of Alzheimer's pathology (2011) (0)
- Structural Neuroimaging Outcomes (2006) (0)
- Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease (2018) (0)
- Chapter 8 Angiotensin-converting enzyme , brain atrophy and cerebral small vessel disease (2013) (0)
- MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA (2014) (0)
- WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2017) (0)
- Lower plasma nutrient levels in people with mild Alzheimer's disease compared with healthy volunteers (2013) (0)
- Clinical differentiation of psychiatric disorders from behavioural variant frontotemporal Dementia: a prospective STUDY (2016) (0)
- MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY (2017) (0)
- ESTABLISHING THE EFFECT OF CODING VARIANTS ON ALZHEIMER’S DISEASE RELATED ENDOPHENOTYPES (2017) (0)
- [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER’S DISEASE SPECTRUM (2018) (0)
- P2-298 Neuropsychiatric and behavioral symptoms do not reflect brain changes as observed on MRI in AD (2006) (0)
- Psychosis in behavioral variant frontotemporal dementia Flora (2017) (0)
- CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS (2017) (0)
- ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER’S DISEASE (2019) (0)
- Increased BACE1 activity in CSF of patients with an Alzheimer biomarker profile (2009) (0)
- Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits. (2022) (0)
- Increased [11C]PET And [18F]FDDNP Binding Are Selectively Associated With Memory Impairment (2009) (0)
- LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER’S DISEASE (2018) (0)
- P4-316 The methionine-homocysteine cycle in the brain of Alzheimer patients (2004) (0)
- GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE (2017) (0)
- FDG-PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELY-DEFINED SUBGROUPS OF ALZHEIMER’S DISEASE (2019) (0)
- CROSS-SECTIONAL STUDIES OF PLASMA PROTEOMIC BIOMARKERS RELATING TO PET AMYLOID AND CSF AMYLOID AND TAU (2016) (0)
- Increased 18F‐flortaucipir load correlates with changes in MEG functional connectivity and network topology, as well as oscillatory slowing (2020) (0)
- CSF Proteome Changes Depend on APOE Genotype in Prodromal AD (2022) (0)
- Souvenir II trial - EEG and MEG (2011) (0)
- DISEASE-STAGE–SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER’S DISEASE (2018) (0)
- The clock drawing test is an important contribution to the Mini Mental State Examination in screening for cognitive impairment (2023) (0)
- changes : the LADIS study independently of cerebral white matter decline and dementia in older people Depressive symptoms predict cognitive (2013) (0)
- LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY (2014) (0)
- QUANTIFICATION OF TAU LOAD USING [18F]AV-1451 AND PET (2016) (0)
- Functional segregation of memory for objects and locations (2000) (0)
- Performing a multi-center imaging study to evaluate the effects of memantine on the rate of brain atrophy in patients with Alzheimer's disease (AD) (2007) (0)
- GREY MATTER CONNECTIVITY IS ASSOCIATED WITH TIME TO CLINICAL PROGRESSION IN MILD COGNITIVE IMPAIRMENT, INDEPENDENT OF AMYLOID STATUS (2016) (0)
- Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data (2015) (0)
- COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE (2014) (0)
- Primary Grey Matter Loss (2011) (0)
- Subject Index Vol. 21, 2006 (2006) (0)
- Automated quantification of small vessel disease brain changes on MRI predicts cognitive and functional decline (2019) (0)
- An eeg study into functional connectivity and hubs in Alzheimer’s disease: What’s going on in the posterior regions? (2015) (0)
- IC-P-100 A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIALVOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER’S DISEASE (2019) (0)
- THINNER CORTICAL THICKNESS IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE IS RELATED TO POOR MEMORY PERFORMANCE AND FASTER DECLINE OF EXECUTIVE FUNCTION (2016) (0)
- P1-334 Distribution of APOE genotypes in a memory clinic cohort (2006) (0)
- Corpus Callosum Atrophy in Alzheimer's Disease and Subcortical Vascular Dementia : The LADIS Study (2010) (0)
- Dementia: Clinical Background (2011) (0)
- First results of the AMYPAD Prognostic and Natural History Study: amyloid‐PET centiloids predicts cognitive functioning in a pre‐dementia population (2022) (0)
- NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN (2014) (0)
- Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia (2009) (0)
- The CognitiveFunctional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the CatchCog study cohort (2020) (0)
- Front & Back Matter (2012) (0)
- DIFFERENT CO-LOCALIZATION OF NEUROINFLAMMATORY MARKERS IN PLAQUES OF ATYPICAL COMPARED TO TYPICAL ALZHEIMER’S DISEASE (2018) (0)
- Complement Activation in Alzheimer’s Disease (2011) (0)
- An RCT to identify best practices for disclosure of amyloid imaging results in mild cognitive impairment: The ABIDE simulation study (2020) (0)
- LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER’S DISEASE (2018) (0)
- PREVELANCE OF AMYLOID IN DEMENTED SUBJECTS (2014) (0)
- Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts (2021) (0)
- CEREBROVASCULAR DISEASE IS ASSOCIATED WITH SLOWER COGNITIVE DECLINE IN ALZHEIMER PATIENTS ON CHOLINESTERASE INHIBITORS (2014) (0)
- P1-054 AN EXPLORATION OFA FUNCTIONAL UNIT OF DNA METHYLATION IN THE AGING BRAIN (2013) (0)
- Contents Vol. 17, 2004 (2004) (0)
- CAPTURING CHANGES IN COGNITION: THE NEEDS AND WISHES OF DEMENTIA RESEARCHERS AND CLINICIANS (2016) (0)
- THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER’S DISEASE CASE-CONTROL STUDIES (2018) (0)
- EFFECTS OF THE MEDICAL FOOD SOUVENAID ON PLASMA NUTRIENT LEVELS IN MILD ALZHEIMER'S DISEASE DURING 48 WEEKS (2014) (0)
- Simon B. N. Thompson, Dementia and Memory: A Handbook for Students and Professionals , Ashgate, Aldershot, Hampshire, 2006, 256 pp., hbk £50.00, ISBN 13: 978 0 7546 4633 4. (2008) (0)
- Reaching a Diagnosis of a Dementia Subtype (2008) (0)
- Genetically identical twin-pair difference models support the amyloid cascade hypothesis. (2023) (0)
- CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER’S DISEASE COMPARED TO CONTROLS (2018) (0)
- Beyond aphasia: Natural history of the aphasia onset dementia syndromes (2020) (0)
- Grey matter network measures are associated with cognitive decline in mild cognitive impairment (2018) (0)
- Urine as matrix for analysis of neurofilament light chain is not suitable to distinguish frontotemporal dementia from psychiatric diseases (2023) (0)
- Medial temporal lobe atrophy and white matter changes are associated with mild cognitive deficits in non-disabled elderly (2005) (0)
- Man with difficulty keeping pace (2011) (0)
- Polygenic risk score for Alzheimer’s disease is related to amyloid positivity in subjective cognitive decline: The SCIENCe project (2020) (0)
- SPPL 2 b is drastically increased in early stages of Alzheimer ’ s disease and associated with tau pathology (2015) (0)
- GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT (2017) (0)
- COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE (2014) (0)
- RETINAL THICKNESS CORRELATES WITH PARIETAL CORTICAL ATROPHY ON MRI (2017) (0)
- Validation and test–retest repeatability performance of parametric methods for [11C]UCB-J PET (2022) (0)
- Rationale and design of the NEwTON study: A prospective cohort study of patients at risk of chronic traumatic encephalopathy (2021) (0)
- Trajectories of decline in cognitively complex everyday activities across the Alzheimer’s disease continuum (2020) (0)
- Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression (2019) (0)
- How to define ‘N’ in the ATN classification in subjective cognitive decline: The SCIENCe project (2021) (0)
- SEX DIFFERENCES IN CEREBROSPINAL FLUID BIOMARKER CONCENTRATIONS ACROSS CLINICAL STAGES OF ALZHEIMER’S DISEASE (2018) (0)
- Attitudes towards genetic susceptibility testing for Alzheimer’s disease dementia in cognitively normal adults: A survey study (2020) (0)
- Everyday functioning in a community‐based volunteer population: Factors associated with concordance between participant and study partner—Report (2021) (0)
- Being physically active is associated with improved executive function and processing speed but not memory: The LADIS study (2013) (0)
- Functional eigenvector centrality dynamics are related to amyloid deposition in preclinical Alzheimer’s Disease (2022) (0)
- DETECTING CLINICALLY RELEVANT CHANGES IN DEMENTIA USING INSTRUMENTAL ACTIVITIES OF DAILY LIVING: A LONGITUDINAL VALIDATION STUDY WITH 3, 6, 9 AND 12 MONTHS FOLLOW-UP (2018) (0)
- Functional brain modularity in Alzheimer's disease (2010) (0)
- Oscillatory Activity of the Hippocampus in Prodromal Alzheimer’s Disease: A Source-Space Magnetoencephalography Study (2022) (0)
- Pseudo-continuous arterial spin-labelling at 3T in Alzheimer disease - initial experience in a memory clinic (2011) (0)
- Synaptic dysfunction reflected in CSF: serial CSF sampling reveals trajectories of potential synaptic biomarkers in early AD stages (2022) (0)
- Amyloid and tau PET relate to memory loss in cognitively normal individuals: the SCIENCe project (2019) (0)
- Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease (2015) (0)
- Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease (2018) (0)
- Annual index (2006) (0)
- omers can disrupt normal neuronal homeostasis by triggering focal accumulation of axonal tau, loss of the polarized distribution of tau and dysregulation of fast axonal transport (2017) (0)
- A RARE GENETIC VARIANT IN THE PLCG2 GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE (2018) (0)
- Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2023) (0)
- A EUROPEAN BIOBANK FOR THE VALIDATION OF NEW MARKERS FOR ALZHEIMER'S AND PARKINSON’S DISEASE: THE BIOMARKAPD PROJECT (2014) (0)
- DISCRIMINATION BETWEEN DEMENTIA WITH LEWY BODIES (DLB), ALZHEIMER’S DISEASE (AD) AND MIXED PATHOLOGY USING ELECTRO-ENCEPHALOGRAPHY (EEG) (2017) (0)
- Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort (2020) (0)
- Harmonization and innovation of cognitive, behavioural and functional assessment in neurodegenerative dementias (2015) (0)
- PREVALENCE AND PROGNOSIS OF PRODROMAL ALZHEIMER'S DISEASE: A COMPARISON OF THE INTERNATIONAL WORKING GROUP CRITERIA AND NATIONAL INSTITUTE OF AGING-ALZHEIMER'S ASSOCIATION CRITERIA (2014) (0)
- Contents Vol. 21, 2006 (2006) (0)
- S.09.01 New concept and new criteria of Alzheimer's disease (2008) (0)
- 2 Early onset APOE Ɛ 4-negative Alzheimer ’ s disease patients show faster cognitive decline on non-memory domains Submitted (2015) (0)
- Magnetic Resonance: Applications in Dementia (2002) (0)
- CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA (2017) (0)
- EARLY ALTERATIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS (2017) (0)
- IC-102-05 Differential effects of white matter lesions on medial temporal lobe atrophy in early versus late onset Alzheimer’s disease (2006) (0)
- Structural and molecular changes along the continuum of Alzheimer's disease (2011) (0)
- The role of ASL-measured cerebral blood flow in the differential diagnosis of Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies (2013) (0)
- Contents Vol. 19, 2005 (2005) (0)
- Erratum : Subcortical ischaemic vascular dementia: A separate disease entity? (Journal of Neurology, Neurosurgery and Psychiatry (2006) 77) (2006) (0)
- LAB-RELATED PRE-ANALYTICAL FACTORS INFLUENCING PLASMA AMYLOID BETA CONCENTRATIONS (2019) (0)
- Psychosocial effects of Corona virus measures on (pre‐)dementia patients during 2nd lockdown (2021) (0)
- P-063 Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment: A longitudinal study (2007) (0)
- THE DIGITAL ALZHEIMER CENTER: A NEXT STEP TOWARD INNOVATIVE DEMENTIA CARE (2014) (0)
- Frontotemporal Dementias: 6th International Conference, Rotterdam, September 2008 (2008) (0)
- PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER’S DISEASE (2018) (0)
- Clinical and neuropsychological features as predictors from MCI to Alzheimer’s-type dementia (2013) (0)
- GREY MATTER CONNECTIVITY IS RELATED TO COGNITIVE IMPAIRMENT IN EARLY AND LATE ONSET AD (2014) (0)
- Subject Index Vol. 26, 2008 (2008) (0)
- Activation in the Hippocampal Region Increases as Function of Encoding Load (1998) (0)
- Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review (2018) (0)
- Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning (2015) (0)
- DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER’S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER’S DISEASE: THE VALUE OF NEUROIMAGING (2019) (0)
- CSF markers as predictors for Alzheimer's disease in subjects with MCI: Effect of APOE genotype-adjusted cut offs (2010) (0)
- Use of recent research criteria for inclusion and use of biomarkers as endpoint in preclinical and prodromal Alzheimer’s disease (AD) trials: An Alzheimer’s disease neuroimaging initiative (ADNI) study (2015) (0)
- MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER’S DISEASE (2017) (0)
- P1-380 Homocysteine metabolism and brain changes in Alzheimer’s disease (2006) (0)
- TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS — THE ABIDE PROJECT (2018) (0)
- METABOLIC BLOOD-BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER’S DISEASE (2018) (0)
- The role of EEG in clinical trials on Alzheimer's disease (2014) (0)
- Effects of Age-Related White Matter Changes on Loss of Corpus Callosum Tissue: The Ladis Study (2010) (0)
- EEG and MRI data in the elderly with or without cognitive impairment (1995) (0)
This paper list is powered by the following services:
Other Resources About Philip Scheltens
What Schools Are Affiliated With Philip Scheltens?
Philip Scheltens is affiliated with the following schools:
